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ABSTRACT 
 
 
MECHANISMS OF SYNAPSE FORMATION AND 
MAINTENANCE:  INSIGHTS FROM THE DEVELOPING AND 
DISEASED NERVOUS SYSTEM  
Ethan G. Hughes 
Rita J. Balice-Gordon, Ph.D. 
 The formation and maintenance of synapses is essential for the central nervous 
system (CNS) to function. In the developing nervous system, the assembly of synaptic 
circuits is a complex and dynamic process, requiring the coordinated exchange of signals 
between pre- and postsynaptic neurons and surrounding glia. The maintenance and 
modulation of synaptic connections is required for normal CNS function and ongoing 
plasticity.  The structural and functional integrity of synaptic connections is often 
modified or lost in the diseased nervous system, resulting in profound cognitive and 
behavioral deficits. While some aspects of the mechanisms underlying the formation, 
maintenance and plasticity of CNS synapses in the developing and diseased nervous 
system have been elucidated, many more remain to be understood. 
 In my thesis work, I have examined the role of astrocytes in the development of 
GABAergic hippocampal synapses in in vitro models.  I have also examined the 
maintenance of glutamatergic synapses in in vitro and in vivo models of anti-NMDAR 
 ii
encephalitis, an immune-mediated disorder of memory and behavior.  First, I demonstrate 
that secreted factors released from astrocytes specifically increase GABAergic axon 
length, branching, and synaptogenesis, that these effects are not mediated by several 
well-known candidates, and that the secreted factors from astrocytes are proteins.  
Second, I examined the identity of the proteins released from astrocytes that affect 
GABAergic neurons using size fractionation, mass spectroscopy, and computational 
analyses. Third, I examined the cellular and synaptic mechanisms underlying anti-
NMDAR encephalitis and investigated the effects of autoantibodies from patients with 
this disorder on the maintenance and function of CNS excitatory synapses. Together, my 
work extends our understanding of how neuron-glial communication modulates the 
formation of synapses in the developing brain, and how the disruption of synapse 
maintenance may underlie cognitive deficits in the diseased nervous system. 
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Introduction 
Part 1:  Neuron-glia signaling in CNS synapse formation 
 
 The assembly of central nervous system (CNS) synaptic circuits is a complex and 
dynamic process, requiring the coordinated exchange of signals between pre- and 
postsynaptic neurons and surrounding glia. Astrocytes, one of the main glial cell types in 
the CNS, have been traditionally considered to act passively in the brain, maintaining 
ionic homeostasis in the extracellular milieu, removing neurotransmitters from the 
synaptic cleft, and providing trophic factors for neurons.  Recently, this view has been 
challenged by evidence that astrocytes can respond to and modulate neuronal signaling. 
While astrocytes participate in the function of neuronal circuitry, other studies implicate 
astrocytes in neuronal process outgrowth and the development and maintenance of 
synaptic connections.  However, until recently the mechanisms by which astrocytes affect 
neurite outgrowth and synapse formation, function and maintenance have been poorly 
understood. 
 
Role of astrocytes in neurite outgrowth 
 The surface of astrocytes and astrocyte precursors are prominent substrates for 
neurite growth during development, and also play an active role in directing axons to 
targets by both promoting and inhibiting axonal outgrowth. Astrocytes express and 
release numerous factors that promote and inhibit neurite outgrowth.  Studies 
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investigating the signals that promote axon growth along astroglia surfaces as in the 
developing optic pathway, have identified cell surface adhesion molecules, such as N-
cadherin and integrins, to be expressed on the surface of astrocytes promote neurite 
outgrowth (Neugebauer et al., 1991).  Interestingly, other cell-surface proteins also 
present on astrocytes, such as chondroitin sulfate proteoglycans, have been shown to 
restrict neurite outgrowth (Smith-Thomas et al., 1994).  In addition to contact-mediated 
factors, astrocytes have also been shown to promote neurite outgrowth through the 
release of diffusible factors.  Biochemical fractionation and purification of astrocyte 
conditioned media has identified extracellular matrix proteins, laminin and fibronectin, 
are released by astrocytes and act to promote neurite outgrowth (Matthiessen et al., 
1989).  Furthermore, astrocytes release trophic factors, such as fibroblast growth factor, 
that stimulate both axonal and dendritic growth of dissociated neurons grown in vitro (Le 
and Esquenazi, 2002).   
 How do astrocytes both promote and inhibit neurite outgrowth? First, there may 
be regional differences in the ability of astrocytes to modulate neurite outgrowth such 
that local astrocytes support outgrowth in a manner distinct from target-derived or other 
cues (Qian et al., 1992). Second, populations of astrocytes within the same region of the 
nervous system may be composed of functionally distinct subtypes, some of which 
support and others that restrict neurite outgrowth (Meiners et al., 1995). Recent work 
shows that astrocyte subtypes in the spinal cord are positionally distinct and are 
determined by the expression of certain homeodomain transcription factors (Hochstim et 
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al., 2008).  Third, neurite promoting properties of astrocytes may be a balance between 
the expression of promoting and blocking molecules (Smith-Thomas et al., 1994). 
Understanding how astrocytes affect neurite outgrowth will not only give us a better 
understanding of how the nervous system develops but also provide insights into the 
diseased nervous system, as astrocytic responses to injury are thought to negatively affect 
axon regeneration (Benfey and Aguayo, 1982; Smith et al., 1986; Tomaselli et al., 1988; 
Silver and Miller, 2004; Rolls et al., 2009).  Together, these studies show that astrocytes 
use both soluble and contact-mediated mechanisms to both promote and inhibit the 
outgrowth of processes from neurons. 
  
Role of astrocytes in the development of synapse structure and function   
 Several lines of evidence suggest that astrocytes also affect the development of 
synapses.  First, astrocytes extend thousands of fine processes that enwrap synapses and 
blood vessels (Ventura and Harris, 1999; Bushong et al., 2002).  Second, the peak of 
astrocyte development overlaps with the formation of synapses during the development 
in vivo (Ullian et al., 2001).  Third, experimental evidence has shown that in purified 
retinal ganglion cell cultures, the presence of astrocytes and/or astrocyte conditioned 
media (ACM) dramatically increases the number of presynaptic contacts, the quantal size 
and efficacy of neurotransmitter release, and the number of postsynaptic AMPA receptor 
clusters (Pfrieger and Barres, 1997; Nagler et al., 2001; Ullian et al., 2001; Ullian et al., 
2004).  Fourth, astrocyte-like glia in C elegans are important for synapse specification 
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and the source of soluble factors that both increase and decrease synapse formation (Shen 
and Bargmann, 2003; Shen et al., 2004; Colon-Ramos et al., 2007; Poon et al., 2008). 
These data suggest that astrocytes, in addition their roles in neurite outgrowth, modulate 
the formation of synapses in the developing nervous system.  
 
Role of astrocytes in the development of inhibitory synapses 
 Since a majority of studies investigating synaptogenesis have focused on the 
formation of excitatory synapses, much less is known inhibitory synaptogenesis.  While 
the components of the inhibitory synapse are clearly defined, the mechanisms regulating 
the construction of inhibitory synapses are less understood.  Recent studies have 
implicated several different processes involving secreted factors, trans-synaptic signaling 
molecules, and transcription factors in mediating the formation of inhibitory synapses.  
The secretion of the neurotrophic factor BDNF not only increases the formation of 
excitatory synapses, but also increases the number of inhibitory synapses formed by 
developing neurons (Vicario-Abejon et al., 1998; Marty et al., 2000).  The trans-synaptic 
adhesion molecule, Neuroligin-2, is localized to inhibitory synapses and induces the 
formation of inhibitory presynaptic terminals when expressed in heterologous cells (Graf 
et al., 2004; Varoqueaux et al., 2004).  In addition, the transcription factor NPAS4 
regulates the expression of activity-dependent genes, which in turn control the number of 
GABA-releasing synapses that form on excitatory neurons (Lin et al., 2008). 
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 Though many studies have investigated the role of astrocytes at excitatory 
synapses, the role of astrocyte signaling in inhibitory synapse formation and function is 
largely unknown.  Astrocytes influence inhibitory synaptic transmission in hippocampal 
slices, where perisynaptic astrocytes release glutamate in response to GABAB receptor 
activation potentiating interneuron GABA release onto pyramidal neurons (Kang et al., 
1998).  Recent work has demonstrated that Bergmann glia of the cerebellum express L1 
family immunoglobulin protein Close Homologue of L1 (CHL1) which directs the 
innervation of inhibitory stellate cells onto their postsynaptic targets (Ango et al., 2008).  
In addition, cortical astrocytes increase the GABA-induced Cl- currents and contribute to 
the maintenance of surface GABAA receptors (GABAARs), the major inhibitory 
ionotropic receptor, in developing hippocampal neurons (Liu et al., 1996; Liu et al., 
1997).  Recent work has shown that astrocytes increase inhibitory synaptogenesis by 
augmenting the number of inhibitory presynaptic terminals and frequency of miniature 
IPSCs, through the modulation neurotrophin signaling between neurons (Elmariah et al., 
2005).  These findings support a role for astrocytes in the formation and function of 
inhibitory synapses as well as excitatory synapses, as previously appreciated. 
 
Role of astrocyte-neuron contact in synapse structure and function   
 The intimate proximity of neurons and astrocytes in the brain raises the question 
of what role astrocyte contact plays in synapse formation and function.  Astrocytes 
ensheathe synapses throughout the hippocampus (Ventura and Harris, 1999) and recent 
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work showed that astrocytes regulate postsynaptic spine morphology through signaling 
between ephrinA3 in astrocyte processes and ephA4 in dendritic spines (Murai et al., 
2003).  Time-lapse microscopy has revealed that astrocytes rapidly extend and retract 
fine processes to engage and disengage motile postsynaptic dendritic spines (Haber et al., 
2006). This activity of astrocytic processes during development can act to stabilize 
dendritic filapodia and possibly lead to their maturation into spines (Nishida and Okabe, 
2007).  
 In addition to playing a role in maintaining synaptic structure and number by 
regulating spine shape, astrocyte contact is important in the plasticity of synaptic circuits.  
In the hypothalamus, withdrawal of astrocyte processes increases the number of synapses 
on the postsynaptic neuron (Theodosis and Poulain, 2001).  Astrocyte contact also 
increases neuronal voltage-gated calcium currents (Mazzanti and Haydon, 2003), and is 
thought to be required for the potentiation of synaptic inputs by D-serine secreted from 
astrocytes (Yang et al., 2003).  
 Beyond roles in regulating synaptic structural and functional plasticity, recent 
work has shown that astrocyte contact with neurons increases excitatory synaptogenesis 
through an integrin-mediated PKC-dependent mechanism (Hama et al., 2004).  These and 
other studies highlight the importance the physical interactions of neurons and astrocytes 
in regulating synapse formation and function. 
 
Role of astrocyte-derived soluble factors in synapse structure and function 
  
7 
 Several lines of evidence suggest that astrocytes coordinately modulate the pre- 
and postsynaptic development of excitatory synapses by soluble as well as contact-
mediated factors.  Glial-derived soluble and contact factors enhance neurite outgrowth 
and synapse formation and function (Pfrieger and Barres, 1997; Ullian et al., 2001; Le 
and Esquenazi, 2002; Ullian et al., 2004).  In purified retinal ganglion cell and spinal 
motor neuron cultures, glia-conditioned medium increased the number of presynaptic 
contacts made between neurons, quantal size and the efficacy of transmitter release and 
increased the number of postsynaptic AMPA receptor clusters (Pfrieger and Barres, 1997; 
Nagler et al., 2001; Ullian et al., 2001; Ullian et al., 2004).  Recent work from the Balice-
Gordon lab has shown that astrocytes also enhance inhibitory synaptogenesis by releasing 
soluble factors that enhance BDNF to TrkB signaling in neurons (Elmariah et al., 2005).  
Additionally, the secretion of the cytokine tumor necrosis factor-α (TNF-α) from 
astrocytes increases postsynaptic efficacy in hippocampal cultures and slices by 
regulating the number of surface AMPA receptors (Beattie et al., 2002).   
 Once mature synapses have formed, astrocytes continue to provide soluble factors 
that regulate synaptic transmission. Several studies have shown that neuronal transmitters 
evoke the release of soluble factors from astrocytes that in turn modulate excitatory and 
inhibitory transmission (Kang et al., 1998; Yang et al., 2003; Zhang et al., 2003; Fiacco 
and McCarthy, 2004).  These effects are mediated in part by astrocyte factors that are 
released via a SNARE-dependent mechanism of vesicular release (Bezzi et al., 2004; 
Mothet et al., 2005; Pascual et al., 2005). 
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Role of astrocytes in synapse maintenance   
 Astrocytes role in synapse formation has been well studied; however, what role 
astrocytes play in the maintenance of synapses is less understood. In the peripheral 
nervous system Schwann cells, a glial cell type that is essential for the development and 
function of neuromuscular junctions (NMJ), are crucial for the maintenance of NMJs.  
Schwann cell ablation at NMJs causes reduced synaptic efficacy of motor nerve terminals 
and retraction after 1 week showing that Schwann cells are essential for the long-term 
maintenance of synaptic structure and function of the adult NMJ (Feng and Ko, 2008). 
 While the role of astrocytes in the maintenance of CNS synapses has not been 
specifically examined, astrocytes have been implicated in playing a role in synapse 
elimination.  Stevens and colleges have shown that immature astrocytes release a soluble 
factor that increases the expression and release of C1q, a protein in the classical 
complement cascade, from neurons and possibly microglia.  C1q then associates with 
synapses and is thought to initiate the complement cascade at unwanted synapses to 
mediate synapse elimination (Stevens et al., 2007).  
 At motor nerve terminals, several candidate molecules are necessary for the 
maintenance of NMJs. While collagen IV chains alpha 2 are necessary for the proper 
development and function of motor nerve terminals, synapse-specific alpha3-6 (IV) 
chains accumulate only after synapses are mature and are required for synaptic maintain 
synaptic terminals (Fox et al., 2007).  Collagens are an essential part of the extracellular 
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matrix and previously have also been shown to be expressed by astrocytes (Heck et al., 
2003).  Future studies examining the role of astrocyte-derived collagens may lead to 
insights into how astrocytes affect the maintenance of CNS synapses. 
 
Identification of astrocyte-factors involved in synaptogenesis   
 Since the initial observations that glia enhance excitatory synaptogenesis (Pfrieger 
and Barres, 1997), investigators have been in search for the candidate molecules 
mediating these effects.  Mauch et al. found that astrocyte-derived cholesterol complexed 
to ApoE was both necessary and sufficient to increase the number of functional 
presynaptic terminals in retinal ganglion cells (RGC) (Mauch et al., 2001).  Recent work 
has also demonstrated that thrombospondin-1 and -2 expressed by immature astrocytes 
can also increase excitatory synapses between RGCs in vitro and in vivo.  These 
immature synapses are presynaptically active but postsynaptically silent, suggesting that 
other, as yet unknown, factors may coordinate pre- and postsynaptic maturation 
(Christopherson et al., 2005).   
 Identification of astrocyte factors that regulate synapse formation has been limited 
by the lack of characterization of the genes and proteins expressed by astrocytes.  
Without efficient purification methods to obtain a sufficiently pure population of 
astrocytes, gene array analyses were not possible. Using different purification strategies 
approaches, two groups have recently profiled the gene expression of in vitro and in vivo 
astrocytes (Lovatt et al., 2007; Cahoy et al., 2008).  These “astrocyte transcriptomes” 
  
10 
provide a view into the inter-workings of astrocytes and show many interesting pathways 
and candidates that can now be examined for their roles in synaptogenesis.  Taking a 
different approach, several other groups have used proteomic approaches to analyze the 
proteins released by astrocytes, or the “astrocyte secretome” (Dowell et al., 2009; Keene 
et al., 2009; Moore et al., 2009).  Translational profiling approaches (Doyle et al., 2008; 
Heiman et al., 2008) and analysis of secreted and membrane-bound molecules by signal-
sequence trap (Spiegel et al., 2006) may yield even more interesting and useful data if 
applied to study astrocytes. These gene and secreted protein profiles of astrocytes will be 
invaluable tools in proceeding forward in the identification of new astrocyte factors and 
their roles in synapse formation. 
 With the discovery of larger numbers of new candidates from genomic and 
proteomic profiles of astrocytes, the evaluation of these potentially interesting candidates 
will be necessary. Several groups have used large-scale screens to identify new molecules 
implicated in synapse formation and synapse specificity (Kurusu et al., 2008; Linhoff et 
al., 2009).  One of these approaches was an unbiased expression screen, where a cDNA 
library screen yielded a new family of trans-synaptic molecules that mediate synapse 
formation (Linhoff et al., 2009). This type of approach on a large and small scale will be 
invaluable to evaluate new candidates identified by the gene expression and secreted 
protein profiles of astrocytes. 
 
Conclusions and future directions 
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 The studies described above begin to define the cellular and molecular 
mechanisms that underlie the communication between neurons and glia that modulates 
synapse formation, function and maintenance.  Evaluating these newly defined pathways 
in intact animals represents an important challenge for future research.  Examining 
neuron-glia communication will be critical to understand how synaptic connections are 
formed and function in the developing and mature brain and will greatly contribute to 
disorders of development such as epilepsy, autism and mental retardation, in which 
synapse formation, function, maintenance are aberrant or reduced. 
 
 
 
Thesis rationale and goals 
 Though many studies have investigated the role of astrocytes at excitatory 
synapses, the role of astrocyte signaling in inhibitory synapse formation and function is 
largely unknown. Previous work from our lab has suggested that astrocytes increase 
inhibitory synaptogenesis by modulating postsynaptic GABAA receptors via BDNF to 
TrkB signaling (Elmariah et al., 2005). Based on these findings, I examined the effects of 
astrocytes on presynaptic aspects of inhibitory synaptogenesis and have identified the 
proteins released by astrocytes that affect GABAergic neurons (Chapters 2, 3). Using 
biochemical, proteomics, and imaging techniques, I tested the hypothesis that astrocyte 
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secreted proteins specifically increase GABAergic axon length, branching, and 
synaptogenesis. 
 My work demonstrates the identity of astrocyte proteins that selectively increase 
GABAergic axon length, branching and the density of functional synapses.  Moreover, I 
show that these proteins differentially affect GABAergic axon outgrowth compared to 
glutamatergic neurons.  Together this work characterizes new roles for astrocytes in 
mediating GABAergic synaptogenesis, highlighting the importance of this glial type in 
the development and maintenance of neural circuits. 
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Part 2: Glutamate receptors in immune-mediated encephalitis 
 
 Glutamate ionotropic receptors, NMDARs and AMPARs, play essential roles in 
synaptic transmission and plasticity and underlie numerous brain functions, including 
learning and memory. The dysfunction of NMDA and AMPA receptors has been 
proposed to result in several well known cognitive disorders, including schizophrenia and 
addiction. However, the mechanisms linking changes in glutamate receptor function to 
changes in behavior remain controversial.  Recently, two new disorders of behavior and 
cognition, anti-NMDAR and anti-AMPAR encephalitis, have been identified and are 
mediated by autoantibodies against glutamate receptors (Dalmau et al., 2007; Lai et al., 
2009).  Patient autoantibodies bind to surface glutamate receptors, leading to their 
internalization and a decrease in receptor mediated synaptic currents, resulting in 
glutamate receptor hypofunction. The reduction or removal of autoantibodies results in a 
recovery of behavioral and cognitive dysfunctions suggesting that the blockade of 
glutamate receptors by autoantibodies is responsible for observed changes in cognition 
and behavior (Dalmau et al., 2008); Hughes et al., in preparation). Thus these new 
disorders have the potential to provide important insights into the functional roles of 
these receptors in memory, behavior and cognition of the normal and diseased brain. 
 
Autoimmunity to synaptic proteins 
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 While there are numerous diseases where synaptic dysfunction correlates to a 
neurological condition, autoimmune disorders provide an opportunity to link a defined 
disease that causes synaptic dysfunction, to circuit dysfunction and, ultimately, 
behavioral dysfunction, and in particular to understand how each recovers once 
autoantibodies are reduced or eliminated. In the peripheral nervous system, immune-
mediated alterations in synaptic structure and physiology are known to cause specific 
neurological disorders. Two well known examples are Myasthenia gravis and Lambert-
Eaton syndrome (Sanders, 2002; Conti-Fine et al., 2006). Patients with these disorders 
develop antibodies that alter the function and density of acetylcholine receptors or 
voltage-gated calcium channels, resulting in characteristic muscle weakness due to 
synaptic dysfunction. Both of these usually improve with immunotherapy and other 
treatments. The autoantibodies that cause these disorders affect synaptic proteins by at 
least three different mechanisms. First, they have been shown to functionally block 
receptors or channels resulting in decreased synaptic function (Gomez and Richman, 
1985; Kim and Neher, 1988). Second, autoantibodies crosslink synaptic proteins which 
lead to their removal from the synaptic membrane by internalization and degradation, a 
process called antigenic modulation (Drachman et al., 1978; Rich et al., 1994).  A third 
mechanism is antibody-mediated activation of the complement cascade which has been 
shown to cause a large portion of the effects of myasthenia gravis. Autoantibodies bind 
the acetylcholine receptor and trigger the complement cascade, which leads to the focal 
destruction of postsynaptic membrane through the recruitment of the membrane attack 
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complex (Lennon and Lambert, 1981; Tuzun et al., 2003). While these and other studies 
have extensively characterized autoimmune disorders affecting neuromuscular synaptic 
proteins, much less is known about autoimmunity to synaptic proteins in the central 
nervous system. 
 
Autoimmunity to glutamate receptors 
 Autoimmunity to glutamate receptors (both NMDA and AMPA receptor subunits) 
has been previously described in patients with epilepsy, systemic lupus erythematosus 
(SLE) and encephalitis. Autoantibodies against the GluR3 subunit of the AMPA receptor 
have been implicated in mediating Rasmussen’s encephalitis, a severe epileptic disorder, 
and several other epilepsies (Rogers et al., 1994; Levite and Ganor, 2008), although the 
association of GluR3 autoantibodies and encephalitis has been controversial (Pleasure, 
2008). Previous work has suggested that some autoantibodies against GluR3 can act as 
AMPA receptor agonists and evoke ion currents (Twyman et al., 1995) which can lead to 
excitotoxic cell death (Levite et al., 1999).  However, other groups have been unable to 
find autoantibodies against GluR3 in patients with Rasmussen’s encephalitis and 
intractable epilepsy, or, when autoantibodies are present; these antibodies did not affect 
AMPA receptor function (Watson et al., 2004). These results suggest that although 
GluR3 autoantibodies may have pathogenic effects, their presence is not characteristic of 
Rasmussen’s encephalitis or epilepsy.  
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 Some studies show that autoantibodies against double-stranded DNA also cross-
react to the NR2A or NR2B subunits of the NMDA receptor in SLE (DeGiorgio et al., 
2001). These autoantibodies that bind DNA and the NR2 subunit of NMDA receptors can 
cause apoptotic death of neurons in vivo and in vitro through an excitotoxic and 
complement-independent mechanisms (DeGiorgio et al., 2001). However, while other 
groups have confirmed the presence of NR2 autoantibodies in some patients with SLE, 
these studies have not found an association of the presence of autoantibodies and 
cognitive dysfunction (Hanly et al., 2006; Harrison et al., 2006; Lapteva et al., 2006). 
These findings suggest that although autoantibodies against NR2 subunits exist in some 
patients with SLE, however, their function and correlation with SLE is less well defined.  
 Autoantibodies against the metabotropic glutamate receptor mGluR1 have been 
identified in two patients diagnosed with cerebellar ataxia after being in remission from 
Hodgkin’s lymphoma (Sillevis Smitt et al., 2000).  These autoantibodies have been 
shown to reduce the basal activity of Purkinje cells and block induction of long-term 
depression (Coesmans et al., 2003).  Another patient with cerebellar ataxia has 
autoantibodies to Homer3, an mGluR1 interacting protein (Zuliani et al., 2007). This 
work suggests that autoimmunity to synaptic metabotropic proteins may result in 
cerebellar dysfunction.  
 Taken together, these studies suggest that autoantibodies against glutamate 
receptors may be present in epilepsy, systemic lupus erythematosus (SLE) and some 
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types of encephalitis. However, more work is needed to establish a causative pathogenic 
effect of these autoantibodies in mediating the symptoms of these disorders. 
 
Anti-NMDAR encephalitis: Human model of NMDA receptor dysfunction 
 Recently, a new disorder has been described by Dalmau and colleges where the 
presence of autoantibodies against the NR1 subunit of the NMDA receptor confirms the 
diagnosis of the behavioral and cognitive dysfunctions associated with the disorder. This 
disorder, anti-NMDA receptor encephalitis, is a severe, potentially lethal, but treatment 
responsive encephalitis that affects children and young adults, predominantly women, 
and manifests with a predictable set of symptoms (Dalmau et al., 2007; Dalmau et al., 
2008); Florance et al., 2009).  Two large cohorts of patients comprising 181 cases show 
that the disorder presents with sudden behavioral and personality changes for which 
patients are often admitted to psychiatric centers and are often misdiagnosed with acute 
schizophrenia  (Dalmau et al., 2007; Dalmau et al., 2008); Florance et al., 2009). Similar 
to autoimmune disorders of the neuromuscular synapse, anti-NMDA receptor 
encephalitis may also occur as a paraneoplastic manifestation of a systemic tumor, mostly 
commonly ovarian teratomas.  Studies show that the frequency of tumor association is 
age- and gender-dependant (Florance et al., 2009).  Despite the severity of the 
neurological syndrome, 75% of patients respond to immunotherapy and when 
appropriate, tumor removal. The recovery occurs over months, with initial resolution of 
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the movement and autonomic symptoms, and then gradual improvement of behavioral 
and memory deficits. 
To investigate the cellular mechanisms underlying the behavioral deficits in anti-
NMDAR encephalitis, the effects of autoantibodies from patients were examined in in 
vitro and in vivo studies of rats. These studies show that autoantibodies decrease the 
surface density and synaptic localization of NMDA receptor clusters via antibody 
mediated capping and internalization, that the magnitude of these changes depends on 
antibody titer, and that these changes are reversible when antibody titer is reduced 
(Dalmau et al., 2008); Hughes et al., in preparation).  Moreover, patient anti-NMDA 
receptor antibodies decrease NMDA but not AMPA receptor mediated synaptic currents, 
consistent with selective loss of surface NMDA receptors (Hughes et al., in preparation). 
These data show that NR1 autoantibodies reversibly alter the number and distribution of 
NMDA receptors in neurons, resulting in a decrease in excitatory synapse function. 
Therefore, the recovery seen in human patients may be due to reversible alterations in 
glutamate receptor synaptic localization and function without wholesale synapse loss.  
Together these results suggest that the cognitive and behavioral deficits in patients are the 
result of autoantibodies causing NMDA receptor hypofunction. 
Previously, NMDA receptor dysfunction has been implicated in several other 
cognitive disorders, including schizophrenia (Olney et al., 1999). Studies investigating 
the effects of phencyclidine (PCP) and ketamine, noncompetitive antagonists of NMDA 
receptors, in human subjects have shown these drugs induce behaviors similar to the 
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positive and negative symptoms of schizophrenia (Luby et al., 1959; Krystal et al., 1994). 
In rodents, these same drugs that block NMDA receptor function also induce 
schizophrenic-like symptoms (Jentsch and Roth, 1999; Mouri et al., 2007). Furthermore, 
mice with reduced NMDA receptor expression show behaviors related to schizophrenia 
(Mohn et al., 1999). Interestingly, patients with anti-NMDAR encephalitis show 
symptoms such as psychotic behavior, signs of involvement of dopaminergic pathways, 
and autonomic instability (Dalmau et al., 2007; Dalmau et al., 2008) that are also caused 
by ketamine and PCP and seen in patients with schizophrenia. This suggests that the 
symptoms of anti-NMDAR encephalitis patients most likely results from NMDA receptor 
hypofunction and may provide new insights into the role of NMDA receptors in behavior 
and cognition. 
 
Anti-AMPAR encephalitis: Human model of AMPA receptor dysfunction 
Anti-AMPAR encephalitis is another recently identified disorder in which 
behavioral and memory deficits are associated with autoantibodies against the GluR1and 
2 subunits of the AMPA receptor (Lai et al., 2009).  This disease is thought to be a 
disorder of learning and memory, as these patients develop seizures and very severe 
short-term memory deficits.  The median age of the first characterized cohort of 10 
patients was 60 years (range 38 - 87); 9 were women; 7 had tumors of the lung, breast or 
thymus.  Nine patients responded to immunotherapy or oncological therapy but with 
frequent neurologic relapses, without tumor recurrence. The presence of neurological 
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relapses and their frequency was correlated with neurological outcome of the patient.  
None of these patient autoantibodies reacted with GluR3, a subunit identified as an auto-
antigen in some patients with Rasmussen’s encephalitis (Rogers et al., 1994; Lai et al., 
2009). 
To begin to characterize the cellular mechanisms underlying anti-AMPAR 
encephalitis, dissociated rat hippocampal neurons were treated with GluR1/2 
autoantibodies. GluR1/2 autoantibodies decreased the synaptic localization of AMPA 
receptors without affecting overall synapse density.  Moreover, as for autoantibodies 
from patients with anti-NMDAR encephalitis, these effects were reversible.  Although 
these disorders share some similar aspects, they are associated with a different clinical 
phenotype. Anti-AMPAR encephalitis patients did not have ovarian teratomas, 
experienced dyskinesias, autonomic dysfunction, or hypoventilation, which are all 
hallmarks of anti-NMDAR encephalitis (Dalmau et al., 2008; Iizuka and Sakai, 2008).  
The trafficking of AMPA receptors to and from synapses mediates the long-term 
potentiation (LTP) and depression (LTD) of synaptic strength, which are thought to 
underlie the cellular basis for learning and memory (Kessels and Malinow, 2009). Since 
the major effect of GluR1/2 autoantibodies was on AMPA receptor synaptic localization, 
these findings suggest that receptor trafficking/turnover is disrupted in this disorder and 
AMPA receptors are moved from the synaptic to the extrasynaptic/intracellular pool 
similar to LTD paradigms. We are currently exploring the cellular mechanisms mediating 
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the effects of GluR1/2 autoantibodies on neurons and synapse function to gain insight 
into the cognitive and behavioral dysfunction in these patients. 
 
New disorders of autoimmunity to synaptic proteins 
Through ongoing screening of patients diagnosed with limbic encephalitis, 
Dalmau and colleagues have identified several new autoimmune disorders with 
autoantibodies against other CNS synaptic proteins. Autoantibodies against GABAB 
receptors (15 patients to date), neurexin (1 patient) and a potassium channel accessory 
subunit (6 patients) have been found in the serum and CSF (Dalmau unpublished data).  
While all of these patients have immune-mediated encephalitis, it is clear that each of 
these emerging groups have distinct neurological symptoms and behavioral 
manifestations.  The generation of animal models of these disorders and further study into 
their underlying mechanisms will be required as these studies move forward. Given the 
importance of synapses in cognition and behavior, the discovery of these disorders may 
provide important human models of synaptic protein dysfunction which may could 
provide greater understanding of the function of synapses in human behavior as well as 
lead to important advances in the treatment of these patients.  
 
Conclusions and future directions 
 The identification of anti-NMDAR and anti-AMPAR encephalitis will provide a 
greater understanding of the role of glutamate receptors in learning, memory and 
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behavior in several different ways. First, the continued generation and examination of 
animal models and patients will help to better understand, recognize, and treat this and 
other immunological diseases that affect cognitive functions.  This is essential because 
not only are these disorders fatal if not recognized and treated appropriately, but earlier 
treatment results in better patient outcomes (Dalmau et al., 2008). Therefore 
understanding the underlying mechanisms may facilitate development of novel 
therapeutic strategies that can more easily identify and treat patients.  Second, these 
disorders provide new human models of glutamate receptor function. Since these 
disorders have an identified pathogenic mechanism and their behavioral and cognitive 
phenotypes can be reversed, they provide a unique opportunity to study these receptors 
and their function in humans.  Finally, understanding the mechanisms that result in 
behavioral deficits in anti-NMDAR and anti-AMPAR encephalitis may provide new 
insights into disease pathways of other psychiatric disorders involving the dysfunction of 
glutamate receptors.  
 
Thesis rationale and goals 
 While the pathogenesis of autoimmune disorders of the peripheral nervous system 
has been well defined, the mechanisms underlying the newly identified disorder, anti-
NMDAR encephalitis, remain poorly understood. Whether this CNS autoimmune 
disorder utilizes similar mechanisms as in the PNS to cause its characteristic cognitive 
and behavioral deficits is unknown. Previous work from our lab has suggested that 
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autoantibodies against the NR1 subunit of the NMDA receptor present in the CSF of 
patients with the disorder may mediate the deficits of this disorder (Dalmau et al., 2008). 
Based on these observations, I examined the effects of autoantibodies in patients with 
anti-NMDAR encephalitis on NMDA receptors in vitro and in vivo (Chapter 4). Using 
biochemical, electrophysiology and imaging techniques, I tested the hypothesis that 
autoantibodies present in patients with anti-NMDAR encephalitis underlie the cellular 
mechanism of this disorder of cognition and behavior. 
My work demonstrates that patient anti-NR1 antibodies reversibly alter the 
number and distribution of glutamate receptors in neurons, resulting in a decrease in 
excitatory synapse function. Moreover, this work has extended our understanding of the 
cellular mechanisms underlying anti-NMDAR encephalitis and, in the future, may 
facilitate a better understanding of the role of NMDA receptors in learning, memory and 
behavior. 
  
24 
Submitted to MCN 
 
Astrocyte secreted proteins selectively increase hippocampal GABAergic axon 
length, branching, and synaptogenesis  
 
Ethan G. Hughes, Sarina B. Elmariah and Rita J. Balice-Gordon 
 
 
Department of Neuroscience, University of Pennsylvania School of Medicine 
Philadelphia, PA, 19104 
 
 
Abstract / Intro / Discussion / Figures / Tables:  143 / 251 / 1023 / 5 / 0 
Supplemental Figures / Tables:  3 / 1 
Key words:  Astrocyte, inhibitory neuron, GABA, axon, synaptogenesis, hippocampus 
 
Address correspondence to:  Rita Balice-Gordon, Ph.D., Dept. of Neuroscience, 
University of Pennsylvania School of Medicine, 215 Stemmler Hall, Philadelphia, PA   
19104-6074 
(215) 898-1037; FAX (215) 573-9122, rbaliceg@mail.med.upenn.edu 
 
  
25 
Abstract 
Astrocytes modulate the formation and function of glutamatergic synapses in the 
CNS, but whether astrocytes modulate GABAergic synaptogenesis is unknown. We 
demonstrate that media conditioned by astrocytes, but not other cells, enhanced 
GABAergic but not glutamatergic axon length and branching, and increased the number 
and density of presynaptically active GABAergic synapses in dissociated hippocampal 
cultures.  Candidate mechanisms and factors, such as activity, neurotrophins, and 
cholesterol were excluded as mediating these effects.  While thrombospondins secreted 
by astrocytes are necessary and sufficient to increase hippocampal glutamatergic 
synaptogenesis, they do not mediate astrocyte effects on GABAergic synaptogenesis.  
We show that the factors in astrocyte conditioned media that selectively affect 
GABAergic neurons are proteins.  Taken together, our results show that astrocytes 
increase glutamatergic and GABAergic synaptogenesis via different mechanisms and 
release one or more proteins with the novel functions of increasing GABAergic axon 
length, branching and synaptogenesis. 
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Introduction 
The development of CNS synapses requires not only the exchange of signals 
between pre- and postsynaptic neurons but also communication with adjacent glia. 
Astrocytes up-regulate the formation of functional glutamatergic synapses through a 
variety of signaling mechanisms; both pre- and postsynaptic effects have been identified 
(Mauch et al., 2001; Hama et al., 2004; Christopherson et al., 2005). In purified retinal 
ganglion cell cultures, astrocyte-conditioned medium (ACM) dramatically increases the 
number of presynaptic contacts made between neurons, the quantal size and efficacy of 
neurotransmitter release, and the number of postsynaptic AMPA receptor clusters (Nagler 
et al., 2001; Ullian et al., 2001; Ullian et al., 2004).  Some of the factors released by 
astrocytes that mediate these effects have been identified.  Astrocyte-derived cholesterol 
complexed to apolipoprotein E (ApoE) increases the number of functional glutamatergic 
presynaptic terminals in retinal ganglion cell autaptic cultures (Mauch et al., 2001).  In 
the cerebral cortex, immature astrocytes express thrombospondins (TSPs), which increase 
the number of ultrastructually normal glutamatergic synapses that are presynaptically 
active but postsynaptically silent (Christopherson et al., 2005).  Thus soluble factors, 
including proteins and lipids, released by astrocytes enhance glutamatergic 
synaptogenesis. 
By contrast, little is known about whether and how astrocytes modulate the 
development of GABAergic synapses.  In earlier work, astrocytes increase GABA-
mediated currents in neurons prior to synaptogenesis (Liu et al., 1996; Liu et al., 1997), 
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but the basis of these effects was not shown.  Here we demonstrate that astrocytes 
increase glutamatergic and GABAergic synaptogenesis via distinct mechanisms and 
release one or more proteins that specifically increase GABAergic axon length, branching 
and synaptogenesis. 
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Results 
Astrocytes selectively increase GABAergic neuron axon length and branching 
GABAergic neuron morphology and neurite outgrowth was examined in 
hippocampal neurons cultured alone or with astrocytes.  At all ages examined, neuron co-
culture with astrocytes or ACM had a profound effect on the length and branching of 
GABAergic axons.  In both culture conditions, GABAergic neurons underwent 
significant growth and maturation during the first two weeks in vitro (Fig. 1; Supp. Table 
1).  In contrast, GAD-negative glutamatergic axons were not significantly longer when 
neurons were cultured with astrocytes or ACM relative to neurons cultured alone (Fig. 1; 
Supp. Table 1).  Cell survival, density,  soma size and number and length of primary 
dendrites of GABAergic neurons or glutamatergic neurons were similar among all culture 
conditions  (Supp. Table 1).  Thus, while neither glutamatergic nor GABAergic axons 
require the presence of astrocytes for growth, astrocyte-derived cues specifically enhance 
the outgrowth of GABAergic axons. 
GABAergic neurons co-cultured with astrocytes or ACM showed significantly 
increased axon branching compared to neurons cultured alone (Fig. 1, Supp. Table 1).  In 
the absence of astrocytes, most GABAergic axons remained unbranched at 4 div and 
exhibited relatively few secondary or tertiary branches at 7 div (Fig. 1; Supp. Table 1).  In 
contrast, GABAergic neurons cultured with astrocytes or ACM had more complex axonal 
arbors than neurons cultured alone during the first 2 weeks in vitro, exhibiting 2 to 3 
secondary branches as early as 4 div (Supp. Table 1).  These effects on branching were 
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not seen for glutamatergic neurons (Fig. 1; Supp. Table 1).  These results demonstrate 
that astrocytes release soluble factors that increase the length and branching of 
GABAergic but not glutamatergic axons. 
 
Astrocytes increase GABAergic synaptogenesis   
We next asked whether astrocytes or ACM caused an increase in GABAergic 
synaptogenesis by assaying the number of GABAergic synapses per length of 
GABAergic axon. Neurons cultured with ACM or astrocytes had ~2-fold more 
GABAergic synapses per 20 μm of axon length than did neurons cultured in the absence 
of astrocytes (Fig. 2A).  ACM increased total GABAergic axon length (sum of the length 
of primary, secondary, and tertiary axon branches) by ~3-fold (Fig. 2B) and the total 
number of synapses by ~7-fold (Fig. 2C).  Thus astrocytes secrete factors that increase 
GABAergic synapse density, independent of increasing GABAergic axon length and 
branching.  
 
Soluble factors specifically released by astrocytes increase GABAergic axon length, 
branching and synaptogenesis 
To determine whether these soluble factors are released specifically from 
astrocytes, we examined the ability of media conditioned by another cell type - primary 
meningeal fibroblasts - to increase GABAergic axon length, branching, and synapse 
density.  We found that 3 days of treatment with fibroblast conditioned media (FCM) did 
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not significantly affect GABAergic axon length or branching at 4 or 7 div compared to 
neurons cultured alone (Supp. Fig. 2 A, B).  Immunostaining for synaptic markers 
showed that FCM treatment did not significantly increase GABAergic synapse density at 
4 or 7 div compared to neurons cultured alone (Supp. Fig. 2C), assayed by the 
colocalization of presynaptic synaptophysin and postsynaptic GABAAR clusters.  Taken 
together, these results suggest that astrocytes, but not fibroblasts, release factors that 
increase GABAergic axon length, branching and synaptogenesis.  
 
ACM increases the number of presynaptically active GABAergic synapses 
To determine whether astrocytes also promote the function of newly formed 
hippocampal synapses, we examined the number of synapses which were labeled with an 
antibody directed to the luminal domain of the vesicular GABA transporter (VGAT), 
which can be used to mark the sites of synaptic vesicle release and recycling (Martens et 
al., 2008).  In neuron-only cultures, there are few GABAergic synapses and both neuron-
astrocyte co-culture and ACM significantly increase the number of GABAergic synapses 
(Fig. 3A, B; see also Fig. 2).  The number of GABAergic synapses labeled with the anti-
VGAT-C luminal antibody (and thus were identified as presynaptically active 
GABAergic synapses) also was significantly increased in neuron-astrocyte co-cultures 
and ACM, compared to neuron only cultures (Fig. 3C).  To examine whether astrocytes 
increase the proportion of functional GABAergic synapses in addition to increasing 
GABAergic synapse number, we plotted the number of functional GABAergic synapses 
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against total GABAergic synapse number per neuron.  Although there are fewer 
GABAergic synapses on neurons cultured alone, the same proportion of GABAergic 
synapses are functional compared to neurons cultured with astrocytes or ACM (Fig. 3 D).  
These data show that astrocytes increase the number but not the proportion of synapses 
that are functional.  Taken together, these results suggest that soluble factors released by 
astrocytes increase the number of GABAergic synapses, and these newly formed 
synapses are functional.  
 
The effects of ACM on GABAergic neurons do not require neurotrophin signaling, 
action potential activity, or cholesterol 
We evaluated several candidate mechanisms mediated by astrocyte soluble factors 
that increase GABAergic axon length, branching and synaptogenesis. First, we blocked 
action potential activity using TTX which had no effect on GABAergic axon length, 
branching, or presynaptic terminal density in neuron-only cultures, and did not alter the 
effect of astrocytes or ACM on GABAergic axon length, branching, presynaptic terminal 
density (Supp. Fig. 3A).  To examine whether neurotrophin signaling mediates the effects 
of astrocytes, we scavenged endogenous BDNF or NT3 using TrkB- or TrkC-IgG fusion 
protein, which did not prevent the increase in GABAergic axon length, branching, or 
presynaptic terminal density in neurons cultured with astrocytes or with ACM compared 
to neurons cultured alone at 7 div (Supp. Fig. 3B, see also (Elmariah et al., 2005)).  
Finally, we examined the role of cholesterol. We found that cholesterol did not increase 
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GABAergic axon length, branching or GABAergic synapse density when compared to 
untreated and vehicle treated cultures (Supp. Fig. 3C; see also (Elmariah et al., 2005)).  
Parallel cultures of neurons grown on astrocytes showed the expected increase in axon 
length, branching, and synapse density. Taken together, these results suggest that the 
effects of ACM on GABAergic neurons do not require neuronal activity, are 
neurotrophin-independent, and cannot be mimicked by addition of exogenous cholesterol. 
 
Effects of astrocytes on GABAergic neurons are not mediated by TSPs 
Recent work has shown that TSPs, in particular TSP-1 and -2, are released by 
astrocytes and mediate the increase in glutamatergic synaptogenesis in retinal ganglion 
cells in vitro and in vivo (Christopherson et al., 2005).  TSPs have also been previously 
shown to increase retinal neurite outgrowth (Neugebauer et al., 1991; DeFreitas et al., 
1995); but see (Christopherson et al., 2005).  Because much of the work on TSPs has 
been done in retinal ganglion cell cultures, we first examined the effects of TSPs on 
hippocampal glutamatergic synapse density.  Treating neuron-only cultures with purified 
TSP-1 increased the number of glutamatergic synapses, by 2-fold at 4 div, mimicking the 
effects of ACM on glutamatergic synaptogenesis (Fig. 4E).  Moreover, immunodepletion 
of endogenously released TSPs from ACM using a combination of antibodies against 
TSP-1 and TSP-2 (Supp. Fig. 4) abolished the increase in glutamatergic synapse density 
mediated by ACM (Fig. 4E).  These results show that TSPs released by astrocytes 
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increase hippocampal glutamatergic synaptogenesis in vitro, similar to previous 
observations in retinal ganglion cells and cortical neurons (Christopherson et al., 2005).  
To examine the role of TSPs on GABAergic axon length, branching and 
synaptogenesis, neuron-only cultures were treated with purified TSP-1.  TSP-1 treatment 
did not significantly increase GABAergic axon length or branching at 7 div compared to 
neuron-only cultures, whereas parallel cultures of neurons and ACM showed the 
expected increases (Fig. 4A, B).  This result shows that TSPs do not mediate these effects 
of astrocytes on GABAergic neurons.   
We next determined whether TSPs could account for the effects of astrocytes on 
GABAergic synapse density.  TSP-1 treatment of neuron-only cultures from 1 to 7 div 
did not affect the density of VGAT+ presynaptic terminals or postsynaptic GABAAR 
clusters per dendrite length, whereas cultures treated with ACM showed the expected 
increases (Fig. 4C, D).  TSP treatment of neuron-only cultures did slightly increase 
GABAergic synapse density.  This increase, however, was significantly less than that 
observed in neurons treated with ACM (Fig. 4 C, D).   Thus, TSPs may increase the 
density of GABAergic synapses, but this does not account for the complete activity in 
ACM that increases GABAergic synapse density by ~4-fold.  
As an additional test of whether TSPs released by astrocytes increase GABAergic 
synapse density, endogenous TSPs were immunodepleted from ACM using a 
combination of antisera against TSP-1 and TSP-2 (Fig. 4C, D). The density of 
GABAergic synapses in neuron-only cultures at 7 div that were treated from 1 to 7 div 
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with TSP-depleted ACM  was significantly higher than in untreated neuron-only cultures, 
but not significantly different in neuron-only cultures treated with ACM.  Thus, in 
contrast to glutamatergic synaptogenesis, TSPs do not appear to be necessary or 
sufficient to increase GABAergic synaptogenesis, suggesting that another factor(s) 
released from astrocytes increase GABAergic axon length, branching, and 
synaptogenesis. 
 
Soluble factors released by astrocytes that increase GABAergic axon length, branching 
and synaptogenesis are proteins 
 To further examine how astrocytes tested whether the biological activity of ACM 
was sensitive to trypsin.  Astrocytes, ACM, ACM + trypsin inhibitor and ACM + 
trypsinized ACM all significantly increased GABAergic axon length, branching, and 
synapse density, compared to neuron-only cultures (Fig. 5).  In contrast, trypsinized 
ACM did not change GABAergic axon length, branching, and the density of GABAergic 
synapses compared to neuron only cultures at 7 div.  Together, these results show that 
factors released by astrocytes that increase GABAergic axon length, branching and 
synapse density are proteins.  
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Discussion 
Here we demonstrate for the first time that astrocytes release proteins that 
selectively increase GABAergic axon length, branching and synapse density.   
Neurotrophins, neuronal activity, cholesterol and TSPs were eliminated as candidate 
mechanisms underlying these effects.  These results show that astrocytes utilize different 
mechanisms to affect glutamatergic compared to GABAergic neurons.  That trypsin 
abolishes the effects of ACM on GABAergic neurons shows that astrocytes release 
proteins that selectively affect GABAergic neurons, expanding the repertoire of glial 
function in the development of neural circuits. 
 
Astrocyte soluble factors increase GABAergic neuron axon length, branching, synapse 
formation and function 
We report for the first time that astrocytes release proteins that selectively 
enhance the development of hippocampal GABAergic neurons by increasing GABAergic 
axon length, branching, synapse density and synapse function.   In the context of previous 
work, our results highlight several important features of astrocyte-neuron signaling 
during development.  First, astrocytes express and release numerous factors, including 
proteins, some of which stimulate neurite outgrowth, including laminin, fibronectin and 
N-cadherins, among others (Tomaselli et al., 1988; Matthiessen et al., 1989; Aoyagi et 
al., 1994).  Recent work suggests that cortical astrocytes also release trophic factors, such 
as fibroblast growth factor, that stimulate both axonal and dendritic growth in postnatal 
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mouse cortical neurons (Le and Esquenazi, 2002).  We found that astrocytes release one 
or more proteins that increase GABAergic axon but not dendrite length and branching.  
Previously identified proteins have not been shown to differentially increase axon 
compared to dendrite length and branching in GABAergic neurons. 
Second, astrocytes secrete proteins that differentially modulate glutamatergic compared 
to GABAergic axonal projections.  We found that astrocytes or ACM did not increase 
hippocampal glutamatergic dendrite or axon length or branching, whereas astrocytes and 
ACM significantly increased GABAergic axon length and branching.  Consistent with 
this, retinal ganglion cell neurite length and branching are not affected by astrocytes or 
ACM (Ullian et al., 2001).  Third, we found that astrocytes increase GABAergic synapse 
density in addition to increasing axon outgrowth.  Together with recent studies on 
glutamatergic synaptogenesis, these results suggest that astrocyte signaling that 
influences axon length and synaptogenesis are separable (Mauch et al., 2001; 
Christopherson et al., 2005).  Finally, our results show that astrocyte secreted proteins 
increase the density of functional GABAergic synapses.  These findings are consistent 
with previous work which showed that astrocyte soluble factors and contact increased the 
number of functional glutamatergic synapses (Ullian et al., 2001; Hama et al., 2004; 
Ullian et al., 2004).  Thus, our works shows that, while astrocytes have some similar 
affects on glutamatergic and GABAergic neurons, they also secrete one or more proteins 
that have differential effects that may lead to key differences in the development of these 
two cell types.  
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The effects of astrocyte soluble factors on GABAergic neurons are not mediated by 
action potential activity, neurotrophins, cholesterol or TSPs 
While previous studies have reported a decrease in GABAergic synaptogenesis 
after chronic blockade of synaptic transmission (Kilman et al., 2002; Hartman et al., 
2006), TTX treatment from 1 to 7 div had no effect on GABAergic synapse number in 
neuron-only cultures, and did not alter the effect of ACM on GABAergic synaptogenesis.  
These different results might be explained by the developmental ages of neurons when 
treated with TTX.  In our experiments, activity was blocked from 1 to 7 div, while in 
previous studies, activity blockade began on or after 5 div (Kilman et al., 2002; Hartman 
et al., 2006).  Thus our work suggests that astrocytes increase GABAergic axon length, 
branching and synaptogenesis via mechanism(s) that are independent of neuronal activity 
during early stages of development.  
Neurotrophin and Trk signaling have been shown to modulate neurite outgrowth 
(Cohen-Cory and Fraser, 1995; McAllister et al., 1996, 1997) and regulate GABAergic 
synapse development (Rutherford et al., 1997; Marty et al., 2000; Seil and Drake-
Baumann, 2000; Yamada et al., 2002).  Moreover, we previously showed that astrocytes 
increase postsynaptic clustering of GABAARs by releasing soluble factors that up-
regulate BDNF-TrkB signaling among neurons (Elmariah et al., 2005).  In the present 
work, we found that after scavenging endogenous BDNF and NT3, ACM still increased 
GABAergic neuron axon length, branching and presynaptic terminal number.  These data 
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demonstrate that neurotrophins do not account for the effects of ACM on GABAergic 
axon length, branching and presynaptic terminal number.   
 Mauch et al. (2001) found that astrocyte-derived cholesterol complexed to ApoE 
was both necessary and sufficient to increase the number of functional presynaptic 
terminals in retinal ganglion cell autaptic cultures.  However, recent studies have found 
that cholesterol is not sufficient to increase hippocampal glutamatergic synaptogenesis 
(Hama et al., 2004), or necessary for retinal ganglion cell glutamatergic synaptogenesis 
(Christopherson et al., 2005).  We find that the addition of cholesterol does not increase 
GABAergic axon length, branching or synaptogenesis.  Therefore, we have eliminated 
cholesterol as a candidate that mediates the effects of ACM on GABAergic neurons.  
 TSP-1 and -2 expressed by immature astrocytes increase the number of 
glutamatergic synapses between retinal ganglion cells in vitro and in vivo 
(Christopherson et al., 2005).  While we confirm that TSPs are required for hippocampal 
glutamatergic synaptogenesis, exogenous TSPs do not mimic the effects of ACM on 
GABAergic neurons.  Furthermore, depletion of TSPs from ACM does not abrogate the 
effect of ACM on GABAergic synaptogenesis.  Thus, TSPs are essential for hippocampal 
glutamatergic synaptogenesis but other astrocyte proteins modulate GABAergic axon 
length, branching and synaptogenesis.    Importantly, these experiments show for the first 
time that hippocampal glutamatergic and GABAergic synaptogenesis are regulated by 
different mechanisms.  
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We have shown that astrocytes release one or more proteins that selectively 
increase GABAergic axon length, branching and the density of functional synapses.  
Moreover, we show that these proteins differentially affect GABAergic compared to 
glutamatergic neurons.  Identifying the proteins that selectively increase GABAergic 
axon length, branching, synapse formation and function, and the relevant downstream 
signaling pathways, is the focus of ongoing work.  Together our results characterize new 
roles for astrocytes in mediating GABAergic synaptogenesis, highlighting the importance 
of this glial type in the development and maintenance of neural circuits. 
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Materials and Methods 
Cell cultures 
 Primary neurons co-cultured with astrocytes were prepared as described 
previously (Elmariah et al., 2005), with minor modifications.  Briefly, hippocampi were 
dissected from embryonic day (E) 18 rats, dissociated in HBSS (Earls Buffered Saline 
Solution (EBSS) with MgCl2 and HEPES) containing 1% papain for 20 min., triturated in 
BME (Basal Medium Eagle), and plated at 75,000-100,000 cells/ml in Neurobasal 
medium (Invitrogen, Grand Island, NY) on poly-L-lysine (1 mg/ml; Sigma, St. Louis, 
MO) coated coverslips in 24-well plates. Cells were grown at 37°C, 5% CO2, 95% 
humidity in Neurobasal medium plus B27 (Invitrogen) that was changed weekly.   
Approximately 15% of the neurons in these cultures have small soma size, less 
branched dendritic arbors, and express GAD.  We have previously shown that, in our 
culture system, activation of GABAARs is depolarizing until 4-5 div; after this time, 
activation of GABAARs is hyperpolarizing (Elmariah et al., 2004).  Since the experiments 
reported here were performed at 4 div and older, for simplicity’s sake, cells and synapses 
that express GABA-related markers are referred to as inhibitory.   
Primary astrocyte cultures were prepared as described previously (Duan et al., 
2003; Zhang et al., 2003).  Briefly, hippocampi were dissected from E18 rats, dissociated 
in HBSS containing 0.25% trypsin for 20 min, triturated in BME, and plated in T25 
flasks in MMEM (Modified Minimum Essential Medium; Invitrogen) supplemented with 
10% heat-inactivated FBS (HyClone, Logan, UT), 2 mM L-glutamine, 14 mM sodium 
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bicarbonate, 40 mM D-glucose, 1% sodium pyruvate and 1% penicillin and streptomycin.  
Astrocytes proliferated for 10 – 14 days; after reaching confluence, they were rinsed in 
cold EBSS and shaken at 260 rpm for 18 - 20 hours in MMEM to remove neurons and 
other cells.  Purified astrocytes were then plated onto poly D-lysine coated coverslips at 
400,000 cells/ml in MMEM.  Medium was changed to Neurobasal medium and 
coverslips used for ACM experiments within 1 - 3 days.  Coverslips were immunostained 
with an antibody against GFAP (Chemicon, Temecula, CA) to assess purity prior to use; 
in the experiments described here, > 98% of the cells were GFAP+. 
For neuron-only cultures, cytosine arabinoside (Ara-C; 10 μM; Sigma) was added 
to cultures 18 – 20 hours after plating to prevent glial proliferation.  For neuron-astrocyte 
co-cultures, the effects of acutely isolated and mature astrocytes (14 – 21 div) were 
compared.  For mature astrocyte co-cultures, neurons were plated onto confluent 
monolayers of astrocytes grown on coverslips and maintained up to 21 div in Neurobasal 
medium.  For neurons cultured with acute astrocytes, neurons were prepared in 
Neurobasal plus B27 supplemented with 5% FBS, 1% L-glutamine, and 1% penicillin 
and streptomycin as described above without the addition Ara-C, allowing astrocyte 
proliferation.  At 4 div, when astrocytes composed approximately 75-80% of cells (N = 
35 coverslips), culture media was changed to Neurobasal medium with B27 and co-
cultures were maintained up to 21 div.  No differences were observed in the effects of 
acutely isolated and mature astrocytes on GABAergic neuron axon length or branching at 
4 div (length: acute 303.9 ± 16.5 (N = 85 neurons), mature 291.7 ± 12.9 (24); # of 2° 
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branches:  acute 3.24 ± 0.33 (85), mature 3.79 ± 0.41 (24); not significantly different, 
Student’s t-test).  Thus, acutely isolated astrocyte co-cultures were used for experiments. 
For neurons cultured with ACM, neurons were plated in Neurobasal medium that 
had been conditioned by astrocytes (14-21 days old) during the previous 72 hours.  
Sterile inserts with 3 μm high pore density polyethylene terephthalate membranes 
(Becton Dickinson Labware, Franklin Lakes, NJ) were placed into each well, and 
coverslips with astrocyte monolayers were inverted 0.9 mm above neurons.  Inserts 
remained in place for the duration of culture.  Neuron-only cultures treated with astrocyte 
inserts or ACM both had increased GABAergic axon length, branching and 
synaptogenesis that were not significantly different from each other (data not shown); 
depending on the experiment, these conditions are interchangeably referred to as ACM.  
Cell survival and density were similar among neurons co-cultured with astrocytes or 
ACM or cultured alone (data not shown, see (Elmariah et al., 2005)).  In addition, neuron 
co-culture with astrocytes or ACM produced no change in the number or length of 
primary dendrites or in the soma size of GABAergic neurons or glutamatergic neurons 
compared to neurons cultured alone (Supp. Table 1).   
Primary meningeal fibroblast cultures were prepared from E18 rat meninges, 
which were dissociated in  0.25% trypsin for 20 min. and plated in T25 flasks in modified 
MMEM supplemented with 10% heat-inactivated FBS, 2 mM L-glutamine, 14 mM 
sodium bicarbonate, 40 mM D-glucose, 1% sodium pyruvate and 1% penicillin and 
streptomycin for 4-7 days before use.  For neurons cultured with fibroblast conditioned 
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media (FCM), neuron-only cultures were plated in Neurobasal medium that had been 
conditioned by fibroblasts for 48 hours.  Sterile inserts with 3 μm high pore density 
polyethylene terephthalate membranes (Becton Dickinson Labware, Franklin Lakes, NJ) 
were placed into each well, and coverslips with fibroblast monolayers were inverted 0.9 
mm above neurons.  Inserts remained in place for the duration of culture. At 1 and 4 div, 
neuron cultures were treated with FCM for 3 days, and immunostained at 4 and 7 div.  
 
Immunostaining and confocal microscopy 
Coverslips were fixed in 4% paraformaldehyde and 4% sucrose for 15 min., 
permeabilized with cold 0.25% Triton X-100 for 5 min., and blocked in 5% normal goat 
serum (Invitrogen) for 1 hour at RT. Triple labeling was performed with combinations of 
primary antibodies:  A2B5 (1:5 dilution, polyclonal; gift of Dr. J. Grinspan), GAD-6 
(1:10, monoclonal; Developmental Studies Hybridoma Bank, Iowa), GalC (1:500, 
monoclonal, gift of Dr. Judy Grinspan), GFAP (1:1000, rabbit antiserum; Sigma), MAP2 
(1:1000, rabbit antiserum; gift of Dr. V. Lee), synaptophysin (1:200, rabbit antiserum; 
NeoMarkers, Fremont, CA), tau (1:1000, rabbit antiserum; gift of Dr. V. Lee), VGAT-N 
(1:200, guinea pig antiserum; Synaptic Systems, Goettingen, Germany), VGAT-C (1:200, 
rabbit antiserum; Synaptic Systems, Goettingen, Germany), and gephryin  (1:200, mouse 
antiserum; Synaptic Systems, Goettingen, Germany).  Antibodies were visualized after 
staining with the appropriate FITC-, TRITC- or CY5-conjugated secondary antibodies 
(all used at 1:200, Jackson ImmunoResearch, Inc., West Grove, PA).  Immunostaining 
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was performed at 4, 7 and 10 div or later ages in vitro with antibodies against glutamic 
acid decarboxylase (GAD), the synthetic enzyme for GABA, to identify GABAergic 
neurons, and tau, to visualize axons. Because synaptophysin labels both glutamatergic 
and GABAergic synapses, and because GABAARs can be transiently clustered beneath 
both types of terminals during development (Rao et al., 2000), immunostaining was 
performed at 7 div with antibodies against the presynaptic vesicular GABA transporter 
(VGAT) and postsynaptic GABAARs or gephyrin to label GABAergic synapses. Images 
were obtained using a confocal microscope (Leica TCS SP2).  In each image, laser light 
levels and detector gain and offset were adjusted so that no pixel values were saturated in 
regions analyzed. 
 
VGAT-C luminal antibody labeling 
Labeling was performed as described previously (Martens et al., 2008).  
GABAergic synapses were identified as clusters in which VGAT-N terminus and 
gephyrin immunostaining were colocalized.  Functional GABAergic synapses were 
identified as clusters in which these markers were also colocalized with VGAT-C 
terminus immunostaining and thus underwent vesicle recycling during stimulation. 
 
Neurotrophin scavenging and TTX, cholesterol and TSP treatment 
Cultures were treated with 2 μg/ml TrkB-IgG, TrkC-IgG or control IgG (gift of 
Regeneron Pharmaceuticals, Inc., Tarrytown, NY) to scavenge neurotrophins.  This 
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scavenger concentration blocked the neurotrophin mediated increase in postsynaptic 
GABAAR clusters (Elmariah et al., 2004, 2005).  1 μM tetrodotoxin (TTX, Sigma) was 
used to block action potentials (Elmariah et al., 2004, 2005).  Treatments began after the 
first day in culture and were replenished every 24 hours until immunostaining was 
performed at 4 or 7 div. For experiments investigating the role of cholesterol, neuron-
only cultures were treated with 10 μg/ml cholesterol (a concentration that increased the 
number of glutamatergic presynaptic terminals in retinal ganglion cell autaptic cultures 
(Mauch et al., 2001); Sigma) or vehicle (EtOH) from 4 -7 div.  For experiments 
investigating the role of TSPs, neuron-only cultures were treated with 5 μg/ml purified 
TSP-1 (Christopherson et al., 2005); Haematological Tech., Essex Junction, VT) from 1 
to 7 div. 
 
TSP immunodepletion 
 Confluent purified astrocyte monolayers were washed with EBSS and treated with 
serum-free medium (Neurobasal plus B27 supplemented with 1% L-Glutamine, and 1% 
penicillin and streptomycin) for 5-7 days.  ACM was filtered to remove cell debris and 
was concentrated 5-10x on Amicon Ultra columns (3-5 kDa; Millipore, Wilmington, 
DE).  Fresh ACM was maintained at 4°C for no longer than 7 days prior to use in the 
bioassays and other samples were stored at -80°C until use.  Concentrated ACM was 
incubated with 50 μl protein A beads (Pierce, Rockford, IL) and 50 μl  protein G beads 
(Amersham, Piscataway, NJ) for 1 hour at RT.  Beads were washed 1x with PBS 
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followed by incubation with a cocktail of the following anti-TSP-1 and -2 antibodies:  0.2 
μg/ml Ab-8 (rabbit antiserum; Neomarkers); 1 μg/ml Ab-2 (monoclonal; Neomarkers); 
10 μl anti-mTSP-1 (monoclonal; gift of Dr. D. Mosher), 10 μl anti-mTSP-2 (monoclonal; 
gift of Dr. D. Mosher) overnight at 4º C.  Antibody bound beads were washed 3x with 
PBS and were added to 300 μl concentrated ACM for 1-3 hours at RT.  Beads were spun 
down and the supernatant was removed and used as TSP-depleted ACM.  To determine 
the amount of TSP depletion, a sample was saved for Western blot analysis before 
addition to neuron-only cultures.  To determine the amount of TSP pulldown, beads were 
washed 3 times with PBS, 3 times with PBS plus 0.25 M NaCl, and 3 times with PBS, 50 
μl  loading dye was added, samples were boiled and analyzed by Western blot.  
 
Trypsinized ACM 
 Trypsinized ACM was prepared by treating concentrated 1 ml of ACM with 10-
100 ng of trypsin for 1 hour at 37 degrees followed by 1 hour incubation with equivalent 
amount of soybean trypsin inhibitor to stop the enzymatic digestion. SDS-PAGE 
followed by silverstain analysis showed that proteins in ACM were digested by trypsin 
treatment (data not shown).  Neuron-only cultures were treated from 1-7 div with ACM 
inserts, ACM media, trypsinized ACM, ACM + trypsin inhibitor or ACM inserts+ 
trypsinized ACM, then immunostained.  Astrocytes, ACM, ACM + trypsin inhibitor and 
ACM + trypsinized ACM all significantly increased GABAergic axon length, branching, 
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and synapse density, compared to neuron-only cultures showing that there are no 
secondary effects of trypsin inhibitor on these cultures (see Fig. 5).   
 
Western blot analyses 
Samples of concentrated ACM, TSP-depleted ACM or TSP bound to beads were 
resolved by SDS-PAGE, transferred to nitrocellulose membranes and probed with 
antibodies against TSP-1 (1.5 μg/ml Ab-2; monoclonal, Neomarkers) or TSP-2 (1:250; 
monoclonal, BDTransduction, San Jose, CA) followed by alkaline phosphatase-
conjugated secondary antibody (1:5000; polyclonal, Applied Biosystems, Foster City, 
CA).  Signals were visualized using chemiluminescence (WesternStar Detection System, 
Applied Biosystems).  Films were digitally scanned and signals were quantified using 
ImageJ software (available at http://rsb.info.nih.gov/ij/). 
 
Quantification and statistical analysis 
For all experiments, 6-15 neurons in each condition were examined on each of 2-3 
coverslips in 3-5 independent experiments.  Neurons were randomly selected for analysis.  
GABAergic neurons were distinguished from glutamatergic neurons by anti-GAD 
immunoreactivity.  In a majority of experiments, the number and proportion of 
glutamatergic and GABAergic neurons were determined by counting GAD+ and GAD- 
neurons in a minimum of 5 randomly chosen fields on each coverslip (750 x 750 
microns).  To assess neuronal morphology, GAD+ soma diameter was measured and the 
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number and length of MAP2+ dendrites and the length of tau+ axons were determined 
from confocal fluorescence images using interactive software (MetaMorph, Molecular 
Devices, Downingtown, PA; or ImageJ).  The number of immunostained pre- or 
postsynaptic clusters was determined from confocal images using interactive software 
(MetaMorph or ImageJ).  To measure synapse density per axon, the longest neurite which 
formed synapses was identified as the axon.  Because of limitations of spectral overlap 
among secondary antibodies and three fluorescence channels, pre- and postsynaptic 
specializations of GABAergic neurons were labeled with VGAT, GABAAR-β3, and 
GAD antibodies; tau antibody wasn’t used to specifically label axons. Confocal images 
of neurons were threshold automatically using an iterative thresholding technique 
(Bergsman et al., 2006), and the number and area of individual clusters were determined 
using interactive software (MetaMorph, Molecular Devices, Downingtown, PA; or 
custom-written ImageJ macros).  Clusters with more than 20% pixel overlap of pre- and 
postsynaptic markers were considered colocalized and thus synaptic. 
Values for axon length, branch number and cluster number were compared across 
conditions using the Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s 
pairwise multiple comparison test, unless otherwise indicated.  All values are presented 
as mean ± s.e.m. 
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Figures and Legends 
 
Figure 2.1  Astrocytes selectively increase GABAergic axon length and branching. 
 Hippocampal neurons were cultured alone, with astrocytes or ACM and were 
immunostained at 4, 7, and 10 div with antibodies against tau (red) and glutamic acid 
decarboxylase (GAD; green).  (A), GABAergic axon length and branching were 
significantly increased in neurons cultured with astrocytes (middle) or ACM (right) 
compared to neurons cultured alone (left) at 4 div (Supp. Table 1).  Areas within white 
boxes are shown below at higher magnification.  Note that GAD expression is dimmer in 
neuron-only cultures compared to neurons cultured with astrocytes or with ACM, as 
represented in these representative figure panels, and confirmed by Western blot analyses 
(data not shown).  Scale bar = 25 (top), 10 (bottom) μm.  (B, C), Quantification of the 
effect of astrocytes or ACM on GABAergic axon length (B, left) and branching (B, right) 
or on glutamatergic axon length (C, left) and branching (C, right).  Asterisk indicates 
significant difference compared to neuron-only cultures (p < 0.001).   
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Figure 2.2  Astrocyte soluble factors increase GABAergic synapse density. 
 (A), GABAergic axon length and branching was significantly increased in 
neurons cultured alone (left) compared to neurons cultured with ACM (right) at 7 div (see 
also Fig. 1, Supp. Table 1).  Scale bar = 10 μm.  Areas within red boxes, shown to the 
right at higher magnification, show presynaptic VGAT (top), postsynaptic GABAARs 
(middle) and their colocalization (bottom).  Neurons cultured with ACM (right) have a 
significantly greater synaptic density than neurons cultured alone (left).  Scale bar = 10 
μm.  (B, C, D), Neurons cultured with ACM have significantly increased GABAergic 
synapse density (B), axon and branch length (C) and total number of GABAergic 
synapses (D) compared to neurons cultured alone. Asterisk indicates significant 
difference (p < 0.05, Student’s t test).   
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Figure 2.3  Astrocyte soluble factors increase GABAergic synapse function. 
(A),  Neurons cultured with astrocytes of ACM have a significantly greater 
number of GABAergic synapses (colocalization of blue and green clusters) labeled by the 
VGAT-C luminal antibody (red) after stimulation compared to neurons cultured alone. 
Scale bar = 10 μm.  (B, C), Quantification of the effect of astrocytes or ACM on 
GABAergic synapse density (B) and functional GABAergic synapse density (C).  
Asterisk indicates significant difference compared to neuron-only cultures (p < 0.001).  
(D), Quantification of the number of GABAergic synapses plotted against the number of 
functional synapses per cell. Data from each condition was fit with a straight line (R2 > 
0.98).  
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Figure 2.4  TSPs do not increase GABAergic axon length, branching, or 
synaptogenesis. 
 Hippocampal neurons were cultured alone, with ACM, with TSP-1, or with TSP-
depleted ACM, and were immunostained at 7 div with antibodies against GAD (green) 
and tau (red) to label GABAergic axons. (A), GABAergic axon length and branching 
were increased in neurons cultured with ACM (middle) but not when neurons were 
treated with TSP-1 (right) compared to neurons cultured alone (left) at 4 div.  Scale bar = 
25 μm.  (B), Quantification shows that GABAergic axon length and branching were 
significantly increased in neurons cultured with ACM compared to neurons treated with 
TSP-1 and neurons cultured alone.  ** indicates significant difference compared to 
neuron-only cultures (p < 0.001).  (C), Hippocampal neurons were cultured alone, with 
ACM, with TSP-1, or with TSP-depleted ACM, and were immunostained at 7 div with 
antibodies against VGAT (red), and GABAAR β3 subunit (green) to label GABAergic 
synapses.  An increase in presynaptic VGAT clusters, postsynaptic GABAAR clusters 
and GABAergic synapse density were observed at 7 div in neurons cultured with ACM 
(middle left) or with TSP-depleted ACM (right) but not when neurons were treated with 
TSP-1 (middle right) compared to neurons cultured alone (left).  Scale bar = 10 μm.  (D), 
Quantification of increase in presynaptic VGAT clusters (left), postsynaptic GABAAR 
clusters (middle) and GABAergic synapse density (right) per length dendrite in neurons 
treated with ACM, TSP-1, or TSP-depleted ACM.  Single asterisk indicates significant 
difference compared to neuron-only cultures (p < 0.050); ** indicates significant 
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difference compared to neuron-only cultures (p < 0.001).  (E), Quantification of increase 
in glutamatergic synapse number per dendrite length in neurons treated with ACM, TSP-
1 but not TSP-depleted ACM. ** indicates significant difference compared to neuron-
only cultures (p < 0.001). 
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Figure 2.5  Astrocyte soluble factors are trypsin-sensitive. 
Hippocampal neurons were cultured alone, with ACM or with trypsinized ACM and 
were immunostained at 4 div with antibodies against GAD and tau to label GABAergic 
axons and VGAT to label GABAergic presynaptic terminals. (A, B), GABAergic axon 
length and branching (A) and GABAergic synapse density (B) were significantly 
increased in neurons cultured with astrocytes (middle) but not with trypsinized ACM 
compared to neurons cultured alone (left).  Scale bar = 25 (top), 10 (bottom) μm.  (C), 
Quantification of GABAergic axon length, branching and synapse density in neuron-only 
cultures cultured with astrocytes, treated with ACM, trypsinized ACM, ACM + trypsin 
inhibitor or ACM + trypsinized ACM. * indicates significant difference compared to 
neuron-only cultures (p < 0.001). 
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Supplemental Figure 2.1  Soluble factors released specifically from astrocytes 
mediate affects on GABAergic neurons. 
 Hippocampal neurons were cultured alone, with astrocytes conditioned medium 
(ACM), or with fibroblast conditioned medium (FCM), and were immunostained at 4 and 
7 div with antibodies against GAD (green) and tau (red) to label GABAergic axons. (A) , 
GABAergic axon length and branching were increased in neurons cultured with ACM 
(middle) but not when neurons were cultured with FCM (right) compared to neurons 
cultured alone (left) at 4 div.  Areas within white boxes are shown below at higher 
magnification.  Scale bar = 25 (top), 10 (bottom) μm. (B), Quantification of the effect of 
ACM or FCM on GABAergic axon length (left) and branching (right). Asterisk indicates 
significant difference compared to neuron-only cultures (p < 0.001).  (C), Hippocampal 
neurons were cultured alone, with ACM, or with FCM, and were immunostained at 4 and 
7 div with antibodies against presynaptic synaptophysin (red), and postsynaptic GABAAR 
β3 subunit (green) to label GABAergic synapses.  An increase in the percent of GABAAR 
colocalization with synaptophysin was observed at 4 and 7 div in neurons cultured with 
ACM (middle) but not when neurons were treated with FCM (bottom) compared to 
neurons cultured alone (top).  Scale bar = 5 μm. (D), Quantification of the effect of ACM 
or FCM on GABAergic synapses. Asterisk indicates significant difference compared to 
neuron-only cultures (p < 0.001).   
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Supplemental Figure 2.2  Astrocyte affects on GABAergic neurons do not require 
action potential activity, BDNF or NT3 signaling or cholesterol. 
 (A), Hippocampal neurons were cultured alone, with astrocytes, or with ACM, 
treated with tetrodotoxin (TTX) were immunostained with antibodies against GAD, tau, 
and VGAT.  TTX treatment had no effect on GABAergic axon length (top), branching 
(middle), or presynaptic terminal density (bottom) in neurons cultured with astrocytes or 
ACM  compared to neurons cultured alone. Asterisk indicates significant difference 
compared to neuron-only cultures (p < 0.001).  (B), Hippocampal neurons were cultured 
alone, with astrocytes, or with ACM, treated with TrkB-IgG or TrkC-IgG were 
immunostained with antibodies against GAD, tau, and VGAT. Compared to control 
cultures treated with IgG (2.0 μg/ml final concentration), TrkB-IgG or TrkC-IgG had no 
effect on GABAergic axon length (top), branching (middle), or presynaptic terminal 
density (bottom) in neurons cultured with astrocytes or ACM at 7 div compared to 
neurons cultured alone. Asterisk indicates significant difference compared to neuron-only 
cultures (p < 0.001).  (C), Hippocampal neurons were cultured alone, with cholesterol or 
vehicle were immunostained with antibodies against GAD, tau, VGAT and GABAAR. 
Cholesterol treatment had no effect on GABAergic axon length (top), branching 
(middle), or GABAergic synapses (bottom) compared to neurons cultured alone. Asterisk 
indicates significant difference compared to neuron-only cultures (p < 0.001).   
  
64 
  
65 
Supplemental Figure 2.3  TSPs are reduced in immunodepleted ACM. 
TSP antibodies were incubated with protein A/G beads, then added to 10-fold 
concentrated ACM.  After incubation, equivalent samples of TSP-depleted ACM were 
compared to ACM incubated with protein A/G beads alone, along with the TSP that was 
bound to the beads. (A),  Immunoblotting with TSP-1 specific antibodies shows that 
TSP-1 is depleted by 80% from ACM, and was bound to protein A/G beads. Asterisk 
indicates significant difference (p < 0.05). (B), Immunoblotting with TSP-2 specific 
antibodies shows that TSP-2 is depleted by 70% from ACM and remains bound to protein 
A/G beads. Asterisk indicates significant difference (p < 0.05). 
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Supplemental Table 2.1  Astrocytes increase inhibitory axon length and branching.
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Abstract 
 
Several molecules are released from astrocytes that increase the formation and 
function of glutamatergic synapses but the molecules that astrocytes secrete to modulate 
GABAergic synaptogenesis are unknown. We demonstrate that media conditioned by 
astrocytes can be separated by gel filtration and biologically assayed for effects on 
GABAergic axon length, branching and synaptogenesis.  We found that gel filtration 
fractions containing high molecular mass proteins and protein complexes mediate the 
effects of astrocytes on GABAergic axon length, branching and synaptogenesis. The 
protein composition of these bioactive fractions was examined using mass spectroscopy 
and computational analyses. We show that these fractions contain at least 223 astrocyte 
secreted proteins. We selected and ranked 34 of these secreted proteins as candidates of 
interest, based on literature searches and biological pathway analysis. I describe the 
approaches we are taking to evaluate these candidates as proteins that mediate the effects 
of astrocytes on GABAergic axon length, branching, and synaptogenesis. Taken together, 
these results show that we have identified a list of proteins that are released from 
astrocytes and that may modulate the formation and function of GABAergic circuitry. 
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Introduction 
The development of CNS synapses requires not only the exchange of signals 
between neurons but also communication with adjacent glia. Astrocytes increase the 
formation of functional glutamatergic and GABAergic synapses through a variety of 
signaling mechanisms including both secreted and contact-mediated factors (Mauch et 
al., 2001; Hama et al., 2004; Christopherson et al., 2005). Recently, several factors that 
increase excitatory synaptogenesis have been identified. Mauch et al. found that 
astrocyte-derived cholesterol complexed to ApoE was both necessary and sufficient to 
increase the number of functional presynaptic terminals in retinal ganglion cells (RGC) 
(Mauch et al., 2001).  Thrombospondin-1 and -2 (TSP) expressed by immature astrocytes 
can also increase excitatory synapses between RGCs in vitro and in vivo.  These TSP 
induced synapses are presynaptically active but postsynaptically silent, suggesting that 
other, as yet unknown, factors may coordinate pre- and postsynaptic maturation 
(Christopherson et al., 2005).  While astrocyte proteins that increase excitatory 
synaptogenesis have been identified, astrocyte factors that increase GABAergic 
synaptogenesis remain unknown. 
 The identification of astrocyte factors that regulate synapse formation has been 
limited by the lack of characterization of the genes and proteins expressed by astrocytes.  
Two groups have recently profiled the gene expression of astrocytes both in vitro and in 
vivo (Lovatt et al., 2007; Cahoy et al., 2008).  Several other groups have used proteomic 
approaches to analyze the proteins released by astrocytes, or the “astrocyte secretome” 
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(Dowell et al., 2009; Keene et al., 2009; Moore et al., 2009).  These approaches, in 
addition to the newly generated gene and secreted protein profiles of astrocytes, will be 
invaluable tools in proceeding forward in the identification of new astrocyte factors and 
their roles in synapse formation. 
In the results presented here, we use a proteomic approach to separate and identify 
proteins released from astrocytes that increase GABAergic axon length, branching, and 
synaptogenesis. We show that astrocyte soluble proteins (or protein complexes) of high 
molecular weight affect these aspects of GABAergic neurons.  Furthermore, we identify 
the protein composition of bioactive fractions using mass spectroscopy and 
computational analyses. Thirty-four proteins were selected as candidates for further 
analysis using literature searches and biological pathway analysis.  I describe the 
approaches we are taking to evaluate these candidates as proteins that mediate the effects 
of astrocytes on GABAergic axon length, branching, and synaptogenesis.  Taken 
together, these results show that we have identified a list of proteins that are released 
from astrocytes and that may modulate the formation and function of GABAergic 
circuitry. 
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Results 
Gel filtration separates ACM proteins by size 
 We concentrated and separated ACM proteins (and protein complexes) by gel 
filtration (a typical chromatogram is shown in Fig. 1A). Silver staining of gel filtration 
fractions run on a denaturing SDS-Page gel showed that ACM are separated by size and 
individual fractions contain relatively small number of bands (Fig. 1B). The first fractions 
collected during gel filtration contained many high molecular weight bands but also 
several lower molecular weight bands (Fig. 1B). This indicates that smaller proteins 
(possibly contained within high molecular weight protein complexes) are present within 
large molecular weight fractions.  These results show that proteins and protein complexes 
released by astrocytes can be separated based on their molecular weight. 
 
ACM proteins in high molecular weight gel filtration fractions affect GABAergic neurons 
 In order to begin to characterize the protein(s) released from astrocytes that affect 
GABAergic axon length, branching and synaptogenesis, we treated neuron only cultures 
of dissociated hippocampal neurons with gel filtration fractions and examined the effects 
on GABAergic neurons. To assess whether fractionation by gel filtration affected the 
ability of ACM to affect GABAergic neurons, we recombined a small amount of each 
fraction into one pool (reconstituted ACM) and treated neuron only cultures. 
Reconstituted ACM increased GABAergic axon length, branching and presynaptic 
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terminal density to a similar extent as unmodified ACM (Fig. 2). These results show that 
ACM proteins retain their biological activity after separation by gel filtration.  
 To examine the size of the protein(s) that mediate the affects of ACM on 
GABAergic neurons, groups of 4 gel filtration fractions were pooled and tested in their 
ability to affect GABAergic neurons. Fractions containing proteins ranging in molecular 
mass of 2000+-860 kDa increased GABAergic axon length, branching, and presynaptic 
terminal density. Additionally, fractions with proteins ranging from 859-360 kDa 
increased GABAergic axon length and branching, whereas fractions with proteins 
ranging from 25-9 kDa only increased the number of GABAergic axon branches. These 
results show that the biological activity mediating the effects of astrocyte conditioned 
media on GABAergic neurons was separated into two fractions, a high molecular weight 
fraction (2000+ - 860 kDa) and a low molecular weight fraction (25 – 9 kDa), each 
having distinct biological activities.    
 
Proteomic evaluation of biologically active gel filtration fractions 
 Biologically active ACM gel filtration fractions were analyzed by tandem mass 
spectrometry (MS/MS) to examine their protein composition. Gel/LC-MS/MS analysis 
identified a total of 772 unique proteins from three samples of high molecular weight 
ACM gel filtration fractions (Supp. Table 1). To specifically examine secreted proteins 
we evaluated the protein identifications using a multi-step computational workflow 
involving in silico cellular localization prediction algorithms and functional Gene 
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ontology (GO) classification. The computation algorithm SignalP (Bendtsen et al., 2004), 
which uses N-terminal signal peptides for subcellular localization prediction, predicted 
186 proteins to contain an N-terminal signal peptide. To include secreted proteins that 
may lack an N-terminal signal, GO analysis was performed using Cytoscape network 
visualization software implementing the BiNGO plug-in. An additional 37 proteins were 
classified that lacked an identifiable signal peptide, but had been annotated to the 
extracellular region (GO: 5 576) or the cell surface (GO: 9 986).Together, these 
computational analyses identified 223 proteins as secreted proteins (Supp. Table 1).  
 Since fractions 1-8 increased GABAergic axon length, branching and 
synaptogenesis (see Fig. 2B), we examined the patterns of separation of secreted proteins 
to help narrow the list of potential candidates. From our experimental findings we predict 
that the protein(s) responsible for increasing GABAergic axon length, branching and 
synaptogenesis would be found in “all fractions” or “not separated” fractions. We found 
that 11 and 30 proteins were uniquely identified in pooled fractions 1-4 and 5-8, 
respectively, while, 39 proteins were identified in both pooled fractions1-4 and 5-8. The 
remaining 143 proteins were not separated into any of these three categories (Fig. 3A). 
 Biological pathway reconstruction provides powerful tools to analyze genomic 
and proteomic profiles (van Baarlen et al., 2008). Ingenuity Pathway Analysis (IPA) is a 
software tool that accelerates the identification of cellular pathways or processes by 
generating protein networks according to biological and functional categories.  We 
selected six pathways identified by IPA as significantly represented in our samples (see 
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Fig. 3C) that may be important in neurite extension and synapse formation. Of the 223 
secreted proteins, ~70 proteins were identified by IPA to be involved in these selected 
pathways. A large portion of these proteins are involved in neurite outgrowth and 
adhesion, whereas a smaller number of proteins are involved in axon guidance, long-term 
potentiation, glial migration, and synaptogenesis (Fig. 3C). 
 To prioritize this group of proteins for candidate testing we developed criteria to 
characterize and rank these potential candidates. Candidates were excluded if i) they 
lacked sufficient evidence of secretion (determined from literature searches, 16 
candidates) or ii) the candidate was not found in more than one condition or experiment 
(8 candidates). To rank candidates we utilized, i) manual literature searches (presence or 
function within neurons or astrocytes) and ii) interest of candidate. Interest of a candidate 
was based on known protein function (determined by literature searches). Candidates 
were grouped into six categories: low interest, interest, high interest, highest interest, 
known candidate (candidate shown to be neuron or glial factor that affects neurite 
outgrowth or synaptogenesis), known candidate (candidate shown to be neuron-glial 
signaling factor that affects neurite outgrowth or synaptogenesis). Using these four 
criteria we identified and ranked 34 candidate proteins released by astrocytes that should 
be tested for their effects on GABAergic axon length, branching, and synaptogenesis 
(Table 2). 
 
Computational and functional classification of potential candidates  
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 Recently, two groups have generated a gene expression profile of astrocytes in 
vitro and in vivo (Lovatt et al., 2007; Cahoy et al., 2008). This astrocyte transcriptome 
provides a view into the global gene expression of astrocytes over development and can 
be compared to gene expression profiles of other cell types (see (Cahoy et al., 2008). We 
utilized this resource to further characterize the candidates we identified from bioactive 
gel filtration fractions (Fig. 3) in astrocytes in vitro, in vivo, and compared to other cell 
types. We examined the presence of the candidates in expression profiles (from (Cahoy et 
al., 2008) of in vitro, in vivo astrocytes and in vivo neurons. Two potential candidates 
were not evaluated in the gene expression profiles generated by Cahoy and colleagues 
(Neural cell adhesion molecule, complement component C3). Of the other candidates, 31 
of the 32 candidates were expressed by astrocytes in vivo, the remaining candidate was 
found to be expressed by astrocytes in vitro (Table 2, presence or absence of gene was 
determined by methods described in (Cahoy et al., 2008)). We examined whether 
candidates were enriched in astrocytes compared to other cell types and conditions. We 
found that 33% of candidates are enriched in astrocytes compared to other cell types 
(neurons, oligodendrocytes), 19% are enriched in astrocytes in vitro, and 43% are 
enriched in astrocytes in vivo. These results suggest that all of our candidates are present 
in astrocytes and many are enriched in astrocytes in vivo. 
 To examine the difference between gene expression values to that of amount of 
secreted protein, we employed semi-quantitative MS based on label-free spectral 
counting. This method has been previously used as an effective means to estimate relative 
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protein abundance (Old et al., 2005).  The number of redundant peptides (spectral counts) 
was normalized by the protein molecular weight for each identified protein. When the 
normalized spectral counts are compared to gene expression values (obtained from 
(Cahoy et al., 2008), some candidates with the highest normalized spectral counts are not 
genes that are highly expressed by astrocytes in vitro (examples: fibronectin, tenascin C). 
This finding suggests that even low expressed genes can produce large amounts of 
protein. Together, these results highlight the importance of the combination of proteomic 
and genomic approaches to characterizing the astrocyte genes and potential candidates 
for mediating the effects of astrocytes on GABAergic neurons.  
  
79 
Discussion 
 Here we demonstrate that astrocyte soluble factors can be separated by size 
exclusion chromatography, evaluated in a bioassay and identified by mass spectroscopic 
and computational techniques. These studies have generated a vast amount of information 
about the proteins that astrocytes release into the extracellular space as well as provided 
insights into potential candidate proteins that may mediate the effects of astrocytes on 
GABAergic neurons.   
 
Candidates shown to mediate astrocytes effects on excitatory synaptogenesis 
 In the context of previous work, our proteomic analysis identifies several 
candidates known to mediate effects of astrocytes on excitatory synaptogenesis.  Our 
analysis identified both thrombospondin-1 and -2 in the largest molecular weight gel 
filtration fractions; fractions that increased GABAergic axon length, branching, and 
synaptogenesis. While thrombospondins (TSPs) are released from astrocytes and increase 
excitatory synaptogenesis both in vitro and in vivo (Christopherson et al., 2005), we have 
previously shown that TSPs are not required for astrocytes to increase GABAergic axon 
length, branching or synaptogenesis (Hughes et al., submitted). We also identified 
apolipoprotein E (ApoE), which is important for mediating the effects of astrocyte 
cholesterol on excitatory presynaptic release (Mauch et al., 2001). However, we do not 
believe that ApoE mediates the effects of cholesterol to increase GABAergic 
synaptogenesis because we have shown that exogenous cholesterol does not increase 
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GABAergic synaptogenesis (Elmariah et al., 2005), see also (Hama et al., 2004; 
Christopherson et al., 2005). Two other candidates identified in our evaluation of 
bioactive gel filtration fractions are SPARC and SPARC-L1. Both SPARC and SPARC-
L1 are released from glia and increase neurite outgrowth (Au et al., 2007) and recently 
have been implicated in inhibiting and promoting excitatory synaptogenesis respectively 
(Eroglu et al., 2007). Since SPARC-L1 increases excitatory synaptogenesis, we tested 
whether SPARC-L1 also increased inhibitory synaptogenesis. We added recombinant 
SPARC-L1 to neuron-only cultures and found no significant increases in GABAergic 
axon length, branching, or synaptogenesis (EGH and RBG unpublished observations) 
suggesting that SPARC-L1 does not mediate the affects of astrocytes on GABAergic 
neurons. Together, these findings suggest that proteins released from astrocytes that 
affect GABAergic neurons have not been previously implicated in mediating the effects 
of astrocytes on excitatory synaptogenesis. 
 
Potential candidates for mediating the effects of astrocytes on GABAergic neurons 
 One potentially interesting candidate identified in the large molecular weight 
fractions that increase GABAergic axon length, branching and synaptogenesis is close 
homologue of L1 (CHL1). CHL1 is a transmembrane molecule that also can function as a 
soluble factor as it can be cleaved from the cell surface by metalloproteases (Naus et al., 
2004). CHL1 is expressed by Bergmann glia in the cerebellum and organize inhibitory 
synapses onto Purkinje cell dendrites (Ango et al., 2008). CHL1-deficient mice have 
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increased numbers of inhibitory synapses and enhanced inhibitory synaptic transmission 
(Nikonenko et al., 2006). Together, these results suggest that CHL1 is important for the 
regulation of inhibitory synapse formation and function in the developing nervous system 
and make it an important candidate to evaluate whether it is mediating the effects of 
astrocytes on GABAergic neurons. 
 Another interesting candidate identified in bioactive gel filtration fractions is 
amyloid beta precursor protein (APP).  APP has been intensively studied for its role in 
the pathogenesis of Alzheimer’s disease, while its normal function is less understood. 
APP is an integral membrane protein expressed in neurons and glia which can undergo 
proteolytic processing to release soluble ectodomains.  These soluble ectodomains are 
important for regulating neurite outgrowth during development (Qiu et al., 1995; Young-
Pearse et al., 2008) and play roles in modulating synaptic transmission, by increasing the 
surface stability of NMDA receptors (Hoe et al., 2009b). Since APP is expressed by 
astrocytes and play roles in neurite outgrowth and synaptic transmission, it is another 
important candidate to determine whether it plays a role in mediating the effects of 
astrocytes on GABAergic neurons during development. 
 One alternative possibility is that multiple proteins interact to exert the effects of 
astrocytes on GABAergic neurons. Since only one large molecular weight fraction 
increases GABAergic axon length, branching, and synaptogenesis, this argues that the 
bioactive protein(s) are at least separated into the same gel filtration fraction. However, 
two proteins identified in this bioactive fraction, amyloid precursor protein (APP) and 
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Reelin, interact to increase neurite outgrowth (Hoe et al., 2009a). Other proteins found in 
bioactive fractions, such as TSP-1, ApoE, and VLDL, interact to play roles in neuronal 
migration (Blake et al., 2008). This evidence suggests that protein interaction and 
biological pathway analysis tools should be used to identify sets or pathways of proteins 
that could be tested to determine whether they regulate the ability of astrocytes to 
increase GABAergic axon length, branching and synaptogenesis. 
 
Evaluating candidates and their affects on GABAergic neurons 
 With the discovery of large numbers of new candidates from genomic and 
proteomic profiles of astrocytes, the evaluation of many potentially interesting candidates 
will be necessary. Several groups have used large-scale screens to identify new molecules 
implicated in synapse formation and synapse specificity (Kurusu et al., 2008; Linhoff et 
al., 2009).  One of these approaches was an unbiased expression screen, where a cDNA 
library screen yielded a new family of trans-synaptic molecules that mediate synapse 
formation (Linhoff et al., 2009). This type of approach on a large and small scale will be 
invaluable to evaluate large numbers of new candidates identified by the gene expression 
and secreted protein profiles of astrocytes. 
 We report the identification of astrocyte soluble proteins in gel filtration fractions 
that increase GABAergic axon length, branching, and presynaptic terminal density. Of 
the 223 identified secreted proteins we intend to focus on 34 candidates based on 
biological pathway analysis and literature searches. We plan to screen these candidates 
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individually by treating neuron only cultures with three different concentrations of the 
recombinant protein for three days and immunostaining these coverslips for GAD and 
VGAT to identify GABAergic neuron neurite morphology and presynaptic terminal 
density. In this manner, we will be able to evaluate these 34 candidates in a relatively 
short period of time. However, despite the reduction in secretome complexity and 
activity-based secretome fractionation using gel filtration, we cannot exclude the 
possibility that the biologically active proteins were not identified below the detection 
limits of the proteomic approach. Based on the initial candidate protein screen, the 
proteomics approach may require further optimization for increased depth of secretome 
analysis. 
 In the results presented here, we use a proteomic approach to separate and identify 
proteins released from astrocytes that increase GABAergic axon length, branching, and 
synaptogenesis. The studies described above begin to define the cellular and molecular 
mechanisms that underlie how astrocytes modulate GABAergic synapse formation, 
function and maintenance.  These studies will be essential to understanding neuron-glial 
communication and the role in play in the development of neural circuits. 
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Materials and Methods 
Cell cultures 
 Primary hippocampal neuronal cultures are prepared as previously described (Goslin 
et al., 1988).  Hippocampi are dissected from embryonic day 18-19 mice, dissociated in 
Ca2+- and Mg2+-free HBSS containing 0.03% trypsin for 20 min., triturated in Dulbecco’s 
Modified Eagle Medium (DMEM; Life Technologies) supplemented with 10% heat-
inactivated fetal bovine serum (FBS) and plated at 100,000 cells per ml in DMEM 
supplemented with 10% FBS, 10% Ham’s F12 (Life Technologies), and 1% Penicillin 
and Streptomycin (Life Technologies) on poly-L-lysine (PLL) coated coverslips in 12-
well plates.  For pure neuronal cultures, cytosine arabinoside (Ara-C; 10 μM) is added to 
cultures 18 – 20 hours after plating to prevent glial proliferation. Culture media is 
changed to Neuralbasal (Life Technologies) supplemented with B27 (Life Tech.) at 4 div.  
Cells are maintained at 37 °C, 5% CO2, 95% humidity; medium is changed weekly. 
 Primary astrocyte cultures are prepared as described previously (Duan et al., 2003; 
Zhang et al., 2003).  Briefly, hippocampi are dissected, rinsed in cold HEPES-buffered 
Earle’s Balanced Salt Solution (EBSS), dissociated in 0.125% trypsin for 20 min., and 
plated in T25 flasks in modified Minimum Essential Medium (MMEM) supplemented 
with 10% heat-inactivated FBS, 2 mM L-glutamine, 14 mM sodium bicarbonate, 40 mM 
D-glucose, 1% sodium pyruvate and 1% Penicillin and Streptomycin.  Astrocytes 
proliferate for 14 – 21 days; after reaching confluency, are rinsed in cold EBSS and 
shaken at 260 rpm for 18 - 20 hours in MMEM to remove neurons and other cells.  
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Purified astrocytes are then plated onto PLL-coated coverslips at 400,000 cells/ml in 
MMEM.  Medium is changed to Neuralbasal Medium and coverslips used for neuron co-
cultures or ACM treatments within 1 - 3 days.  Coverslips are immunostained with an 
antibody against GFAP (Chemicon) to assess purity prior to use. 
For pure neuronal cultures treated with ACM, neurons are plated in Neuralbasal 
Medium conditioned by astrocytes or fibroblasts (14-21 days old) during the previous 24-
72 hours.  Sterile inserts with 3 μm high pore density membranes (BD Labware) were 
placed into each well, and coverslips with astrocyte monolayers were inverted 0.9 mm 
above neurons.  Inserts remain in place throughout the culture duration. 
 
Immunostaining and confocal microscopy 
Coverslips were fixed in 4% paraformaldehyde and 4% sucrose for 15 min., 
permeabilized with cold 0.25% Triton X-100 for 5 min., and blocked in 5% normal goat 
serum (Invitrogen) for 1 hour at RT. Triple labeling was performed with combinations of 
primary antibodies:  GAD-6 (1:10, monoclonal; Developmental Studies Hybridoma 
Bank, Iowa), GFAP (1:1000, rabbit antiserum; Sigma), tau (1:1000, rabbit antiserum; gift 
of Dr. V. Lee), and VGAT-N (1:200, guinea pig antiserum; Synaptic Systems, 
Goettingen, Germany).  Antibodies were visualized after staining with the appropriate 
FITC-, TRITC- or CY5-conjugated secondary antibodies (all used at 1:200, Jackson 
ImmunoResearch, Inc., West Grove, PA).  Immunostaining was performed at 4, 7 and 10 
div or later ages in vitro with antibodies against glutamic acid decarboxylase (GAD), the 
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synthetic enzyme for GABA, to identify GABAergic neurons, and tau, to visualize axons. 
Images were obtained using a confocal microscope (Leica TCS SP2).  In each image, 
laser light levels and detector gain and offset were adjusted so that no pixel values were 
saturated in regions analyzed. 
 
Quantification and statistical analysis for confocal images 
For all experiments, 6-15 neurons in each condition were examined on each of 2-3 
coverslips in 3-5 independent experiments.  Neurons were randomly selected for analysis.  
GABAergic neurons were distinguished from glutamatergic neurons by anti-GAD 
immunoreactivity.  In a majority of experiments, the number and proportion of 
glutamatergic and GABAergic neurons were determined by counting GAD+ and GAD- 
neurons in a minimum of 5 randomly chosen fields on each coverslip (750 x 750 
microns).  The number of immunostained presynaptic clusters was determined from 
confocal images using interactive software (custom-written ImageJ macros).  Confocal 
images of neurons were threshold automatically using an iterative thresholding technique 
(Bergsman et al., 2006), and the number and area of individual clusters were determined 
using interactive software (custom-written ImageJ macros).  Clusters with more than 20% 
pixel overlap of pre- and postsynaptic markers were considered colocalized and thus 
synaptic. 
Values for axon length, branch number and cluster number were compared across 
conditions using the Kruskal-Wallis nonparametric ANOVA test followed by Dunn’s 
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pairwise multiple comparison test, unless otherwise indicated.  All values are presented 
as mean ± s.e.m. 
 
Gel filtration   
 Concentrated ACM is filtered through 0.22 µm membranes, and injected on the 
HPLC for gel filtration analysis using an Agilent (Palo Alto, CA) 1100 series HPLC 
controlled by ChemStation software (Agilent). 1.2 mg of ACM in a total volume of 250 
µl is resolved onto a Superdex 200 HR10/30 column (GE Healthcare Bio-Sciences, 
Uppsala, Sweden) for size exclusion chromatography (SEC) analysis.  ACM proteins are 
resolved at a flow rate of 0.3 ml/min in 25 mM HEPES, pH 7.25, and 150 mM NaCl.  
Fractions (0.5 ml) are collected and concentrated with 5000 NMWL Ultrafree-MC filters 
(Millipore). The gel filtration column is calibrated using the following mixture of 
globular proteins standards: thyroglobulin (669 kDa, 85 Å), ferritin (440 kDa, 61 Å), 
catalase (232 kDa, 52.2 Å), aldolase (158 kDa, 48 Å), albumin (67 kDa, 35.5 Å), 
ovalbumin (43 kDa, 30.5 Å), chymotrypsin (25 kDa, 20.9 Å), and ribonuclease A (13.7 
kDa, 16.4 Å). The void volume is determined from the elution migration of blue dextran 
(2000 kDa, 99 Å).  Protein elution is monitored by UV absorbance at 275 nm.  All 
experiments involving gel filtration chromatography are performed initially at RT.  
Fractionated samples are stored at -80 °C until use.  Neurons are treated with fractions 
diluted 1:20 in NeuralBasal medium and assayed after 72 hours. 
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Electrospray Tandem MS Analysis of Astrocyte-conditioned Media   
 Tryptic digests of fractions from gel filtration (prepared as described in Zuo and 
Speicher, 2000) are analyzed on an LTQ linear IT mass spectrometer (Thermo Electron) 
coupled with a NanoLC pump (Eksigent Technologies, Livermore, CA) and autosampler.  
Tryptic peptides are separated by RP-HPLC on a nanocapillary column, 75 μm id x 20 
cm PicoFrit (New Objective, Woburn, MA, USA), packed with MAGIC C18 resin, 5 μm 
particle size (Michrom BioResources, Auburn, CA). Solvent A is 0.58% acetic acid in 
Milli-Q water, and solvent B is 0.58% acetic acid in acetonitrile (ACN). Peptides are 
eluted into the mass spectrometer at 200 nL/min using an ACN gradient.  Each RP-LC 
run consists of a 10 min. sample load at 1% B; a 75 min. total gradient consisting of 1–
28% B over 50 min., 28–50% B over 14 min., 50–80% B over 5 min., 80% B for 5 min 
before returning to 1% B in 1 min.  To minimize carryover, a 36 min. blank cycle is run 
between each sample.  Hence, the total sample-to-sample cycle time is 121 min.  The 
mass spectrometers are set to repetitively scan m/z from 375 to 1600 followed by data-
dependent MS/MS scans, the ten most abundant ions with dynamic exclusion enabled. 
 
Protein Identification and Validation   
 Proteins are identified from the MS/MS spectra using the SEQUEST Browser 
program (Thermo Electron).  DTA files are generated from MS/MS spectra using an 
intensity threshold of 5000 and minimum ion count of 30. The DTA files generated are 
processed by the ZSA, CorrectIon, and IonQuest algorithms of the SEQUEST Browser 
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program, and searched against the NCBI non-redundant protein database 
[www.ncbi.nlm.nih.gov/RefSeq/].  Databases are indexed with the following parameters: 
average mass range of 500–3500, length of 6–100, tryptic cleavages with 1 internal 
missed cleavage sites, static modification of Cys by carboxyamidomethylation (+57 Da), 
and variable modification of methionine (+16 Da). The DTA files were searched with a 
2.5 Da peptide mass tolerance and 0 Da fragment ion mass tolerance.   
 Potential sequence-to-spectrum peptide assignments generated by SEQUEST are 
loaded into Scaffold (version Scaffold-01_06_17, Proteome Software Inc., Portland, OR) 
to validate MS/MS based peptide and protein identifications as well as to compare 
protein identifications across experimental conditions.  Peptide and protein probabilities 
were calculated by the Peptide and Protein Prophet algorithms, respectively.  A protein 
identification is accepted if it meets one of the following three criteria: (1) ≥ 99.0% 
protein confidence and ≥ 3 unique peptides at 95% probability,  (2) ≥ 99.0% protein 
confidence, 2 peptides at ≥ 50% probability, and satisfied (1) in another condition, or (3) 
≥ 99.0% protein confidence, 1 peptide at ≥ 50% probability, and satisfied (1) in a 
biological duplicate.  Proteins identifications not assigned are manually inspected.   
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Figures and Legends 
 
Figure 3.1  Proteins in astrocyte conditioned media are separated based on 
molecular weight by gel filtration. 
 (A), UV spectra of eluted protein as astrocyte conditioned media was separated by 
size exclusion chromatography. Fractions (0.5 ml) were collected at the indicated times. 
Pooled (B) and individual (C) fractions (2.0 μl) were examined by SDS-Page followed by 
silver stain analysis.  
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Figure 3.2  Large molecular weight gel filtration fractions increase GABAergic axon 
length, branching and synaptogenesis. 
 Hippocampal neurons were cultured alone, with astrocytes, ACM, or pooled gel 
filtration fractions for 3 days were immunostained at 4 div with antibodies against tau 
(red) and glutamic acid decarboxylase (GAD; green) and vesicular GABA transporter 
(VGAT, blue). (A), GABAergic axon length, branching, and presynaptic terminal density 
were significantly increased in neurons cultured with reconstituted ACM (far left) and 
high molecular weight fractions (middle left) compared to neurons cultured with mid-
range molecular weight fractions (middle right) at 4 div. GABAergic axon branching was 
significantly increased in neurons cultured with low molecular weight fractions (far right) 
compared to neurons cultured with mid-range molecular weight fractions (middle right) 
at 4 div.  Areas within white boxes are shown below at higher magnification. Scale bar = 
25 (top), 10 (bottom) μm. (B), Quantification of the effect of astrocytes, ACM, 
reconstituted ACM, or ACM gel filtration fractions on GABAergic axon length (white), 
branching (black) or presynaptic terminal density (gray).  Asterisk indicates significant 
difference compared to neuron-only cultures (p < 0.001).   
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Figure 3.3  Proteomic evaluation of biologically active gel filtration fractions 
 (A), Mass spectroscopic analysis of bioactive fractions yielded approximately 800 
proteins. Using a multi-step computational workflow we identified approximately 225 of 
these proteins to be secreted. (B), Histogram of the number of secreted proteins present in 
all fractions analyzed, only in fractions 1-4, or only in fractions 1-8. (C), The number of 
secreted proteins included identified by IPA to be important in six pathways important in 
neurite extension and synapse formation. 
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Table 3.1  Potential candidates of secreted astrocyte proteins that may mediate the 
effects of astrocytes on GABAergic neurons. 
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Supplemental Table 1  Mass spectroscopic and computational analyses of biological 
active ACM gel filtration fractions. 
 An interactive excel spreadsheet containing all proteins identified by mass 
spectroscopic analysis. 
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Abstract 
 Autoimmunity to synaptic proteins is the cause of well known disorders of 
neuromuscular transmission, such as myasthenia gravis and Lambert-Eaton syndrome, 
but it is much less known as cause of central nervous system disorders.  We recently 
described a severe, potentially lethal, but treatment responsive encephalitis associated 
with autoantibodies to the N-terminal extracellular domain of the NR1 subunit of the N-
methyl-D-aspartate (NMDA) receptor.  This disorder predominates in young women and 
children who develop a predictable set of symptoms, including prominent psychosis, 
bizarre behavior, and memory deficits, and frequently have an underlying tumor (mostly 
ovarian teratoma) that expresses NMDA receptors. Symptoms often respond to 
immunotherapy or tumor removal, suggesting an immune-mediated pathogenesis.  Here 
we demonstrate, using in vitro studies, that patients’ antibodies cause a decrease of 
surface density and synaptic localization of NMDA receptor clusters via antibody 
mediated capping and internalization. The magnitude of these changes correlates with 
antibody titer, and the effects are reversed when antibody titer is reduced.  Moreover, 
patients’ antibodies decrease NMDA but not AMPA receptor mediated synaptic currents, 
consistent with a selective loss of surface NMDA receptor clusters. We also demonstrate 
using in vivo studies that NMDA receptor cluster density is dramatically reduced in the 
hippocampus of rats infused with patients’ antibodies as well as in the brain of autopsied 
patients with this disorder. These studies establish the cellular mechanisms by which 
antibodies of patients with anti-NMDA receptor encephalitis alter NMDA receptor 
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density, localization and function, which are critical for learning, memory and other 
behaviors. 
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Introduction 
Synaptic plasticity is thought to underlie mechanisms of memory, learning, and 
cognition. Central to these neurological functions is the proper synaptic localization and 
trafficking of the excitatory glutamate NMDA and AMPA receptors.  The roles of these 
receptors at the synaptic and cellular levels have been established through animal models 
in which the receptors have been genetically or pharmacologically altered (Jentsch and 
Roth, 1999; Mouri et al., 2007).  In humans the role of these receptors in memory, 
learning, cognition and psychosis comes from more indirect approaches, such as 
pharmacological trials (e.g., NMDA receptor antagonists causing psychosis), and analysis 
of brain tissue from patients with Alzheimer’s disease or schizophrenia in which several 
molecular pathways causing a downstream alteration of glutamate receptors are affected. 
We recently identified a disorder in which the NR1 subunit of the NMDA receptor is 
directly targeted by autoantibodies (Dalmau et al., 2007; Dalmau et al., 2008). Patients 
develop prominent psychiatric and behavioral symptoms, rapid memory loss, seizures, 
abnormal movements (dyskinesias), hypoventilation, and autonomic instability.  In two 
series comprising 181 cases, there was a strong female predominance (ratio 8.5:1.5) and 
the median age of the patients was 19 years (23 months-75 years; 40% children). Most 
patients presented with bizarre behavior, agitation, delusions, hallucinations and 
catatonia, leading to admissions to psychiatric centers for suspected psychosis or 
schizophrenia. In 55% of the adults (less frequently in children), the disorder appears to 
be triggered by the presence of a tumor, mostly an ovarian teratoma that contains nervous 
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system tissue and expresses NMDA receptors. Despite the severity of the symptoms 75% 
of patients recover after receiving immunotherapy and, when appropriate, tumor removal, 
and 25% are left with memory and cognitive deficits, impulsiveness, inappropriate 
behavior, or, rarely, die of the disorder. The autoantibodies are present in patients’ serum 
and cerebrospinal fluid (CSF), the latter usually showing intrathecal synthesis and high 
antibody concentration. All patients’ antibodies recognize the N-terminal extracellular 
domain (amino-acid residues 25-380) of NR1, suggesting an antibody-mediated 
pathogenesis. We previously showed that patients’ antibodies cause a decrease in surface 
NMDA receptor cluster density, but the underlying mechanisms were unexplored.  Here 
we report in vitro and in vivo studies that establish the cellular mechanisms by which 
patients’ antibodies lead to a reduction in surface and synaptic NMDA receptor density 
and function, likely underlying the learning, memory and other behavioral deficits 
observed in patients with anti-NMDA receptor encephalitis. 
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Results  
 
Patients’ antibodies reduce surface NMDA receptor clusters and protein in a titer 
dependent fashion 
 Rat hippocampal neurons were cultured for 14 days were treated 1 day with CSF 
or purified IgG containing anti-NR1 antibodies determined by ELISA (Dalmau et al., 
2007) from 10 patients, followed by immunohistochemical and Western blot analyses of 
surface and total NR1 protein. Patients’ antibodies decreased NR1 or NMDA receptor 
surface and total cluster density in a titer dependent fashion, compared to CSF or IgG 
from control patients (Fig. 1A, C). Similar results were obtained with Western blot 
analyses of cell surface and total NR1 protein (Fig. 1B, D). Moreover, Western blot 
analyses of the effect of patients’ antibodies on NR2 subunits (which assemble with NR1 
to form NMDA receptors) showed that patients’ antibodies decreased surface and total 
NR2A and NR2B proteins in a titer dependent fashion (Supp. Fig. 1). 
To determine whether the effects of patients’ antibodies correlate with the change 
of titers during the course of the disease, hippocampal neurons were cultured with CSF 
samples obtained at two different time points of the disease of three patients. The initial 
CSF was obtained at the time of symptom presentation and the second sample during 
symptom improvement in two patients and symptom worsening in the third patient. In the 
first two patients the CSF obtained at symptom presentation had a higher NR1 antibody 
titer than the CSF obtained during symptom improvement, while in the third patient the 
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CSF obtained during symptom worsening had a higher antibody titer than the CSF 
obtained at symptom presentation.  In all 3 patients, the CSF with higher NR1 antibody 
titer decreased NMDA receptor surface and total cluster density (or total NMDA receptor 
protein measured by Western blot) (Fig. 1E, F) to a greater extent than the CSF with the 
lower titer. Together, these results show that NR1 antibodies from patients with anti-
NMDA receptor encephalitis decrease NMDAR surface cluster density and protein in a 
titer-dependent manner and that in each individual the effects of the antibodies vary with 
the change of titers during the course of the disease. 
 
Patients’ antibodies reversibly reduce synaptic NMDA receptor clusters without 
affecting the number of synapses and other synaptic components 
 Because patient antibodies decreased overall NMDA receptor surface cluster 
density and protein, we determined whether the antibodies also affected NMDA receptor 
synaptic localization, the number of synapses, and other synaptic components. 
Hippocampal neurons were cultured with CSF or purified IgG for 3 or 7 days, followed 
by immunostaining or Western blot analysis of NR1 and synaptic components such as 
presynaptic VGlut, postsynaptic PSD-95, AMPA receptor subunits GluR1 and GluR2, 
and GABA receptors. Patients’ antibodies did not affect the number of excitatory 
synapses compared to controls (Fig. 2A, B). Moreover, patients’ antibodies did not affect 
the density of postsynaptic PSD-95, GluR1, GluR2 or GABA receptor clusters, or the 
surface or total amount of these proteins (Supp. Fig. 2), dendritic branching, dendritic 
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spine density (Supp. Fig. 3, 4), or cell survival (Supp. Fig. 8). These results show that 
patient antibodies specifically affect NMDA receptors without affecting AMPA or 
GABA receptors, other synaptic proteins, the number of excitatory synapses, and 
neuronal morphology or viability. 
 While the overall structural integrity of excitatory neurons and synapses was not 
affected, we found that patients’ antibodies dramatically reduced the synaptic localization 
of NMDA receptor clusters compared to controls (Fig. 2A, C), consistent with the overall 
decrease in surface NMDA receptor cluster density (Fig. 1).  Since patients who receive 
early treatment often fully recover, we investigated whether the antibody-mediated 
decrease in NMDA receptor synaptic localization was reversible.  Patient antibodies were 
removed from the culture medium after 3 days of treatment and neurons were cultured for 
4 additional days.  The density of synaptically localized NMDA receptor clusters 
returned to baseline levels 4 days after patient antibodies were removed (Fig. 2A, C).  
These results show that patients’ antibodies cause a specific loss of NMDA receptors 
from excitatory synapses and that this loss is reversed after antibody removal. 
 
Patients’ antibodies selectively decrease synaptic NMDA currents 
 We next assessed the effects of patient antibodies on NMDA receptor function 
using whole-cell patch recordings of miniature excitatory postsynaptic currents 
(mEPSCs), which consist of a fast AMPA receptor-mediated current and a slow NMDA 
receptor current.  Neurons were treated for 1 day with patient or control CSF and 
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spontaneous inward currents were recorded at -70 mV in a 0 Mg2+ extracellular solution 
to unmask synaptic NMDA receptor-mediated mEPSCs.  CNQX was used to block 
AMPA receptor-mediated mEPSCs and APV was used to block NMDA receptor-
mediated mEPSCs (Fig. 3A). 
 Patient antibody treatment did not affect mEPSC frequency or amplitude (Supp. 
Fig. 4), consistent with structural analyses that showed that patients’ antibodies do not 
affect the number of excitatory synapses (mEPSC frequency) or the number of 
postsynaptic sites containing AMPA receptors (mEPSC amplitude).  
In neurons treated for 1 day with CSF from control patients, CNQX blocked 
large, fast AMPA receptor mediated currents, revealing small, slower NMDA receptor 
mediated currents that were completely blocked by APV (Fig. 3A, left).  In contrast, in 
neurons treated for 1 day with patient CSF, CNQX blocked all mEPSCs, and no further 
reduction was observed after APV (Fig. 3A, right).  This result shows that there is very 
little NMDA receptor mediated current in neurons treated with patient antibodies.   
 To quantify the reduction in synaptic NMDA receptor mediated currents, currents 
were examined before and after APV application.  In neurons treated for 1 day with CSF 
from control patients, APV reduced or abolished the late, slow NMDA receptor mediated 
component of the mEPSC (Fig. 3B, left; 3C, left).  In contrast, in neurons treated for 1 
day with patient CSF, APV application did not further reduce the NMDA receptor 
mediated component of the mEPSC (Fig. 3B, right; 3C, left).  No difference was 
observed in the peak AMPA receptor mediated component of the mEPSC (Fig. 3C, 
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right).   These results show that patients’ antibodies specifically decrease synaptic 
NMDA receptor mediated currents and do not affect AMPA receptor mediated currents, 
consistent with the specific loss of surface, synaptically localized NMDA receptor 
clusters.   
 
Patients’ antibodies crosslink and internalize NMDA receptors 
 We next determined the mechanism by which patient antibodies decrease surface 
NMDA receptor cluster density and protein.  The Fc IgG domain was enzymatically 
removed from patients’ antibodies to generate Fab fragments.  These Fab fragments, like 
intact patient IgG, bound to surface NR1 clusters identified with commercial anti-NR1 
immunostaining (Supp. Fig. 5).  Neurons were treated for 1 day with patients’ antibody 
Fab fragments had the same NMDA receptor cluster density and surface protein as 
neurons treated with control IgG (Fig. 4A, B). In contrast, neurons treated for 1 day with 
patients’ Fab fragments and anti-Fab secondary antibodies (linking two Fab fragments in 
a confirmation similar to unmodified patients’ antibodies) had significantly lower NMDA 
receptor cluster density and surface protein as compared to neurons treated with control 
IgG (Fig. 4A, B).  These results show that patients’ antibodies mediate the loss of surface 
NMDA receptors in part by binding to, capping and crosslinking NMDA receptors, 
resulting in their internalization (Fig. 4C).   
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Patients’ antibodies decrease NMDA receptor cluster density and protein in rodent 
and human hippocampus in vivo  
 Our results show that, in vitro, patients’ anti-NR1 antibodies lead to a selective 
loss of surface NMDA receptor clusters and their function, without loss of other synaptic 
components or neuron viability. To determine the effects of patients’ antibodies in vivo, 
CSF from patients with high titers of NR1 antibodies, or control CSF from individuals 
without NR1 antibodies, was infused directly into the hippocampus of adult rats for two 
weeks, followed by immunostaining for human IgG to examine the diffusion and 
deposition of patients’ antibodies, immunostaining and Western blot analysis of NMDA 
receptors and other synaptic components to determine the effects of patients antibodies, 
and assessment of cell death using the TUNEL assay.  Patient antibodies colocalized with 
NMDA receptor clusters in vivo as in vitro (Supp. Fig. 7).  Moreover, infused patient 
IgG, but not control IgG, was found bound to rat hippocampus in a predictable pattern 
that was dependent on NMDA receptor density (e.g., high density in proximal dendrites 
of dentate gyrus, data not shown).  This pattern was similar to the direct immunostaining 
of bound IgG reported in the autopsy of two patients with anti-NMDA receptor 
encephalitis (Dalmau et al., 2007).  
 Patients’ CSF infusion into rat hippocampus caused deposition of human IgG in 
the hippocampus (Supp. Fig. 8).  Moreover, in regions where human IgG was deposited, 
there was a significant decrease in NMDA receptor cluster density and intensity of NR1 
immunostaining without affecting the number of synapses, the density of other synaptic 
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components (Fig. 5A-E; Supp. Fig. 8) or cell death (Supp. Fig. 8).  The magnitude of the 
effects of each patient’s CSF correlated with the titer of NR1 antibodies infused into rat 
brains (Fig. 5B), as demonstrated in in vitro studies (Fig. 1).  Furthermore, the total 
amount of NR1 protein was reduced in rodent hippocampus infused with patient 
compared to control CSF (Fig. 5C).     
 To investigate whether NMDA receptor cluster density is reduced in the brains of 
patients with anti-NMDA receptor antibodies, paraffin-embedded sections of the 
hippocampus of two patients with anti-NMDA receptor encephalitis and the hippocampus 
of three age-matched, anti-NR1 negative, neurologically normal individuals were 
immunostained with anti-NR1 antibodies.  The density of NMDA receptor clusters was 
substantially decreased in patients’ hippocampus compared to controls (Fig. 5F-H). 
Moreover, deposits of human IgG, but not complement, were identified in some of the 
regions with reduced NMDA receptor clusters (data not shown). These data show that 
patient anti-NMDA receptor antibodies reduce NMDA receptor cluster in rodent neurons 
in vitro and in vivo as well as in patient brain. 
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Discussion 
Anti-NMDA receptor encephalitis is a recently described disorder that is 
associated with antibodies against the NR1 subunit of the NMDA receptor and results in 
a well defined set of symptoms. Our previous studies noted that the resulting syndrome 
resembled the phenotype of animals in which the NMDA receptor function had been 
attenuated pharmacologically or genetically, suggesting that patients’ antibodies 
decreased NMDA receptor levels. We now demonstrate using in vitro and in vivo studies 
that patients’ antibodies decrease the surface density and synaptic localization of NMDA 
receptor clusters via antibody mediated capping and internalization, independent of the 
presence of complement, and without affecting other synaptic proteins, AMPA receptors 
or synapse density. The magnitude of these changes depends on antibody titer, and the 
effects are reversible when the antibody titer is reduced.  Moreover, patients’ NR1 
antibodies decrease NMDA, but not AMPA, receptor mediated synaptic currents.  Thus 
the selective loss of surface clusters abolishes NMDA receptor mediated synaptic 
currents.  These findings indicate that NR1 antibodies from patients with anti-NMDA 
receptor encephalitis decrease glutamatergic synaptic function without a substantial loss 
of synapses. 
This reversible loss of NMDA receptors, and the resulting synaptic dysfunction, 
may underlie the deficits of memory, behavior and cognition that are hallmarks of anti-
NMDA receptor encephalitis (Dalmau et al., 2008). Indeed, a remarkable feature of this 
disorder is the frequent reversibility of symptoms, even when these are severe and 
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protracted. Previous studies showed a correlation between clinical outcome and antibody 
titer, which is usually higher in CSF than serum due to intrathecal antibody synthesis. 
The work we present here demonstrates that the effect of patients’ CSF on surface 
NMDA receptors is correlated with the change of antibody titers and symptom severity 
during the course of the disease.  When comparing different patients, a similar correlation 
was found between CSF antibody titers and the intensity of effects on NMDA receptors, 
but there was inter-patient variability between antibody titers and severity of patients’ 
symptoms (data not shown). This variability is common to most autoimmune disorders, 
and is likely due to patient-specific related factors (e.g., age, fever, poorly controlled 
seizures) and the fact that analysis of CSF provides the closest, though imperfect, 
assessment of the immune response within the brain.  In the current study, analysis of the 
hippocampus of two patients who died of this disorder showed a substantial decrease of 
NMDA receptor levels compared with the hippocampus of three age-matched, 
neurologically normal individuals. This decrease of NMDA receptors was comparable to 
that observed in rats infused with patients’ antibodies. Moreover, we previously reported 
that patients’ hippocampus showed deposits of IgG and absence of complement (Dalmau 
et al., 2007), consistent with the complement-independent antibody effects demonstrated 
in in vitro studies.  
In the peripheral nervous system, immune-mediated disruption of synaptic 
structure and function results in well known disorders of neuromuscular transmission 
such as myasthenia gravis and Lambert-Eaton syndrome (Sanders, 2002; Conti-Fine et 
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al., 2006). Anti-NMDA receptor encephalitis provides a new model of central nervous 
system synaptic autoimmunity, antigenically different but mechanistically similar to 
Lambert-Eaton syndrome in which autoantibodies, but not monovalent Fab fragments, 
crosslink and internalize voltage-gated calcium channels, without complement activation. 
Both disorders may occur as paraneoplastic manifestation of a tumor that expresses 
neuronal proteins (e.g., small-cell lung cancer in Lambert-Eaton) or contains ectopic 
nervous tissue (e.g., teratoma in anti-NMDA receptor encephalitis). Moreover, in both 
disorders the immunological trigger of cases without tumor association is unknown, 
although a genetic predisposition to autoimmunity has been demonstrated or suggested. 
Although both disorders respond to immunotherapy and when appropriate tumor 
removal, the response of anti-NMDA receptor encephalitis is slower and less predictable, 
particularly in cases with delayed diagnosis or without a detectable tumor. These patients 
usually have persistently high CSF antibody titers, despite the effectiveness of plasma 
exchange or IVIg in reducing serum antibody titers. In these cases, symptoms frequently 
respond to cyclophosphamide, which crosses the blood-brain barrier, or rituximab, which 
depletes memory B-cells. As postulated in other disorders, these cells are able to cross the 
blood-brain-barrier, and are believed to undergo re-stimulation, antigen-driven affinity 
maturation, clonal expansion, and differentiation into antibody-secreting plasma cells.  
NMDA receptor dysfunction has been implicated in several other cognitive 
disorders, including schizophrenia (Olney and Farber, 1995).  Studies investigating the 
effects of phencyclidine and ketamine (noncompetitive antagonists of NMDA receptors) 
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in human subjects show these drugs induce behaviors similar to the positive and negative 
symptoms of schizophrenia, along with repetitive orofacial and limb movements, 
autonomic instability, and seizures (Luby et al., 1959; Krystal et al., 1994).  In rodents, 
drugs that antagonize NMDA receptor function induce cataleptic freeze, and locomotor 
and stereotype behaviors, consistent with schizophrenia-like manifestations (Jentsch and 
Roth, 1999; Mouri et al., 2007).  Furthermore, mice with decreased expression of NR1 
have similar behavioral deficits, while mice lacking NR1 develop breathing problems and 
die in the perinatal period (Mohn et al., 1999).  Interestingly, most patients with anti-
NMDA receptor encephalitis present with acute schizophrenia-like symptoms and are 
admitted to psychiatric institutions before they develop catatonia, catalepsy, stereotyped 
movement disorders, and frequent autonomic instability and hypoventilation. The striking 
similarity between these phenotypes, the effect of patients’ antibodies resulting in a 
dramatic decrease of surface NMDA receptor clusters and function, and the reduced 
levels of NMDA receptors in autopsied patients, support an antibody-mediated 
pathogenesis of anti-NMDA receptor encephalitis.  The psychosis and cognitive and 
behavioral deficits in patients with anti-NMDA receptor encephalitis most likely result 
from NMDA receptor hypofunction, directly and indirectly affecting synapse and circuit 
structure and function in regions that bind anti-NR1 autoantibodies.  Thus the findings we 
report here also support the hypothesis that NMDA receptor hypofunction underlies 
many manifestations of schizophrenia. Future studies will focus on the circuit-level 
dysfunction caused by patient antibodies in hippocampus and other brain regions, to 
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begin to connect synaptic and circuit dysfunction with the behavioral abnormalities that 
are hallmarks of this disorder.   
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Materials and Methods 
Preparation of patient and control CSF and IgG  
Patient or control cerebrospinal fluid (CSF) was collected and filtered using 
protein A/G sepharose columns.  CSF was diluted 1:15-50 to treat neurons in vitro.  In 
some experiments, IgG purified from serum was used to treat neurons (Fig. 1D, F; Fig. 
4).  Both patient CSF and patient IgG decreased surface and total NMDA receptors to the 
same extent (Supp. Fig. 6).  Furthermore, the effects of patient CSF on NMDA receptor 
cluster density were not mediated by complement, because heat-inactivated patient CSF 
decreased NMDAR cluster density and localization to a similar extent as non-heat 
inactivated patient CSF (Supp. Fig. 6). Briefly, 10 ml of patient or control serum were 
incubated with a 5 ml column of protein A/G Sepharose beads (50:50) for 30 min. on an 
orbital shaker at 4 °C.  After elution IgG was added to a bio-spin chromatography column 
(Bio-Rad) followed by 3 washes with PBS, eluted with 100 mM glycine, pH = 2.5 and 
neutralized with Tris-HCl, pH = 8.0,  dialyzed against PBS and concentrated to stock 
solutions of 20 mg/ml and stored at -80 °C.  IgG concentration (~1mg / ml) and pH (7.4) 
were adjusted prior to use.  Each CSF or IgG preparation was tested for antibody 
reactivity by staining mouse or rat brain sections or HEK cells expressing NR1/NR2 
heteromers of the NMDAR as previously described (Dalmau et al., 2007; Dalmau et al., 
2008).   
 
Cell culture and patient antibody treatment 
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 Primary rat hippocampal neuron and astrocyte cultures were prepared from 
embryonic day 18-19 (Goslin et al., 1988).  Briefly, hippocampi were in Ca2+ free HBSS 
containing 1% papain for 20 min., triturated in Basal Media Eagle (BME; Invitrogen) 
supplemented with B-27 (Life Technology) and plated at 100,000 or 400,000 (for 
biotinylation) cells per ml in Neural Basal (NB; Life Technologies) supplemented with 
10% FBS (Hyclone), B-27, 1% penicillin and streptomycin (Life Technologies) and 1% 
L-Glutamine (Life Technologies) on poly-L-lysine coated (Sigma) coverslips in 24-well 
plates.  Culture media was changed to NB  supplemented with B27 at 4 div.  Cells were 
maintained at 37 °C, 5% CO2, 95% humidity; medium was changed weekly. 
  
Immunostaining for pre- and postsynaptic components   
To stain surface NMDAR clusters, control or treated neurons were washed in NB 
plus B27 and were incubated with patient CSF containing anti-NR1 antibodies for 30 
min., washed and incubated with fluorescently conjugated anti-human secondary 
antibodies for 30 min., and washed in PBS.  Neurons were then fixed in 4% 
paraformaldehyde, 4% sucrose in PBS, pH = 7.4 for 15 min., permeabilized with cold 
0.25% Triton X-100 for 5 min., and blocked in 5% normal goat serum (Invitrogen) for 1 
hour at RT.  Additional immunostaining was performed with various combinations of 
primary antibodies:  to label glutamate receptors, anti-NR1  (1:1000; Chemicon), anti-
GluR1 (1:10; CalBioChem) or anti-GluR2/3 (1:100; Chemicon); to label dendrites, 
chicken anti-MAP2 (1:5000; AbCam); to label presynaptic terminals, mouse anti-SV2 
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(1:200; DHSB); guinea pig anti-VGLUT 1 (1:5000; Chemicon), or mouse anti-Bassoon 
(1:400;  Stressgen Bioreagents).  Antibodies were visualized after staining with the 
appropriate fluorescently conjugated secondary antibodies (1:200, Jackson 
ImmunoResearch). 
 
Confocal imaging, image analysis and statistical analysis   
 For all experiments, 6-12 randomly selected pyramidal neurons, identified by 
morphology (Elmariah et al., 2004; Elmariah et al., 2005) in each condition were imaged 
using confocal microscopy (Leica TCS 4D system) on each of 2-3 coverslips in 3-5 
independent experiments.  Images were thresholded automatically using an iterative 
thresholding technique (Bergsman et al., 2006), and the number and area of individual 
immunostained pre- or postsynaptic clusters were determined using interactive software 
(custom-written ImageJ macros).  Clusters with more than 20% pixel overlap of pre- and 
postsynaptic markers were considered colocalized and thus synaptic.  Cluster density was 
compared among conditions using the Kruskal-Wallis nonparametric ANOVA test 
followed by Dunn’s pairwise multiple comparison test, unless otherwise indicated.  All 
values are presented as mean ± s.e.m. 
 
Biotinylation of surface proteins and analysis by Western blot   
Neurons were treated with 1 μg – 1 mg/ml IgG for 1 day, washed with PBS 
supplemented with 0.1 mM CaCl2 and 1 mM MgCl2 (rinsing buffer) and incubated for 30 
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min. at 4 °C with 1 mg/ml Sulfo-NHS-Biotin (Thermo Scientific) in rinsing buffer.  
Neurons were then washed with rinsing buffer + 100 mM glycine (quenching buffer), 
incubated in quenching buffer for 30 minutes at 4°C to quench excess biotin, then lysed 
in RIPA buffer (150 mM NaCl, 1 mM EDTA, 100 mM Tris HCl, 1% Triton X-100, 1% 
sodium deoxycholate, 0.1% SDS, pH 7.4, supplemented with 1:500 protease inhibitor 
cocktail III, Calbiochem) at 4 °C for 1 hour.  Lysates were cleared of debris by 
centrifugation at 12400 x g for 20 min. An aliquot of the remaining supernatant was taken 
for the lysate fraction, and a second aliquot was incubated with avidin-linked agarose 
beads (Immobilized Monomeric Avidin, Thermo Scientific) overnight at 4 °C.  After 
centrifugation, the supernatant was removed and the beads (surface fraction) were 
washed 1X RIPA buffer, 2X high-salt wash buffer (500 mM NaCl, 5 mM EDTA, 50 mM 
Tris, 0.1% Triton X-100, pH 7.5), and 1X no-salt wash buffer (50 mM Tris, pH 7.5). The 
surface fraction was eluted from the beads with 2X sample buffer and proteins separated 
on an 8% gel using SDS-PAGE.  Samples were transferred to nitrocellulose membranes 
and probed for antibodies against NR1 (1:1000, 556308, BD Pharmingen), NR2A 
(1:1000, AB1555, Millipore; 1:500, MAB5216, Millipore; 1:500, A6473, Invitrogen), 
NR2B (1:1000, AGC-003, Alomone; 1:500, 06-600, Upstate), GABAARα1 (1:1000, 06-
868, Upstate), GABAARα2 (1:500, AB5984, Chemicon), GluR 2/3 (1:1000, 07-598, 
Upstate), PSD-95 (1:1000, 610496, BD Pharmingen), and actin (1:2000, A2066, Sigma). 
Actin and GABAARs were used as loading controls for total and surface fractions, 
respectively. Blots were incubated with HRP-conjugated goat anti-mouse or goat anti-
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rabbit secondary antibodies (1:3000, Cell Signaling), and signals were visualized using 
chemiluminescence (SuperSignal Chemiluminescent Substrate, Thermo Scientific). All 
quantified films were in the linear range of exposure, were digitally scanned and signals 
quantified using NIH ImageJ. 
 
Whole cell electrophysiological recordings of synaptic NMDA and AMPA receptor 
mediated currents 
Whole cell voltage clamp recordings were performed as previously described 
(Elmariah et al., 2004; Elmariah et al., 2005) from 14 – 21 div pyramidal neurons treated 
for 24-48 hours with patient CSF containing anti-NR1 antibodies, control CSF or left 
untreated.  Briefly, neurons were incubated in extracellular physiology solution without 
Mg2+ (in mM:  119 NaCl, 5 KCl, 2 CaCl2, 30 Glucose, 10 HEPES, pH = 7.4).  Voltage-
clamp recordings were made at RT (22-25 °C) using glass microelectrodes (resistance 4-
6 MΩ) filled with a Cesium substituted intracellular solution (in mM:  100 Cesium 
gluconate, 0.2 EGTA, 5 MgCl2, 2 ATP, 0.3 GTP, 40 HEPES, pH = 7.2).  Pipette voltage 
offset was neutralized before the formation of a gigaohm seal. Membrane resistance, 
series resistance, and membrane capacitance were determined from current transients 
elicited by a 5 mV depolarizing step from a holding potential of -80 mV, using the whole 
cell application of HEKA software.  Criteria for cell inclusion in the data set included a 
series resistance ≤ 30 MΩ and stability throughout the recording period.  Currents were 
amplified, low-pass filtered at 2.5 kHz, and sampled at 5 Hz using HEKA software.  
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Miniature excitatory spontaneous currents (mEPSCs) were recorded at -70mV in the 
presence of TTX (1 µM) and Picrotoxin (10 µM).  APV (50 µM) and CNQX (10 µM) 
were bath applied to block NMDAR and AMPAR mediated currents respectively.   
mEPSC events were detected and analyzed using MiniAnalysis (Synaptosoft, Leonia, 
NY), which employs a threshold-based event-detection algorithm.  NMDAR and 
AMPAR components of mEPSCs were separated temporally by their distinct kinetics 
(Hestrin et al., 1990; Watt et al., 2000; Yang et al., 2003). The amplitude of the NMDAR 
mediated current was determined in a window between 15 and 25 ms after the peak of the 
AMPAR mediated component, which has a fast, < 1 ms rise time.  All values are 
presented as mean ± s.e.m. 
 
Fab fragments preparation and treatment 
Fab fragments were prepared from serum IgG using a kit according to the 
manufacturer’s directions (Fab preparation kit, Pierce Protein Research Products, Thermo 
Scientific).  Briefly, serum IgG was digested for 2-4 hours at 37 °C with 1% (w/w) 
papain pH= 7.0 with 0.01 M cysteine, resulting in cleavage into Fab and Fc fragments.  
Fab fragments were then isolated by chromatography and concentration determined by 
absorption at 280 nm.  Fab fragments were used to treat neurons at a concentration of 4 
μg/ml.  Control experiments showed that incubating neuron with patient Fab fragments 
for 30 min. resulted in surface staining of NR1 clusters (Supp. Fig. 5).  
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Alzet mini-pump placement, IgG infusion and sectioning 
Young adult rats (6-8 weeks old) were anesthetized and a cannula placed into the 
left lateral ventricle using predetermined coordinates (AP 0.6 mm, lateral 1.6 mm to 
bregma and horizontal 2.0 mm to the dura mater).  The cannula was attached to a head 
probe mounted to the skull.  The cannula was attached to an Alzet minipump (Alzet brain 
infusion kit #3, pump model 2002) placed subcutaneously on the back and attached to the 
head probe via sterile tubing.  Patient or control CSF was then delivered at a rate of 0.5 μl 
/ hr  for 2 weeks.  Rats were then euthanized, brain tissue harvested, immersion fixed in 
4% paraformaldehyde in PBS, pH = 7.4 for 15 min., cryoprotected in 30% sucruose in 
PBS, pH = 7.4 overnight at 4 °C, frozen in isopentane cooled in dry ice, and frozen 
sections obtained at 20 μm.  Sections were immunostained using one or more of the 
primary and fluorescent secondary antibodies, confocally imaged and images thresholded 
and analyzed as described above.   
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Figure Legends 
 
Figure 4.1  Patient antibodies reduce surface NMDA receptor clusters and protein 
in a titer dependent fashion. 
 (a) Hippocampal neurons immunostained for surface, total NMDA receptor 
clusters and the presynaptic terminal marker Bassoon. Treatment with patient CSF for 1 
day reduces the density of surface and total NMDA receptors without affecting 
presynaptic terminal density. Scale bar = 10 μm. (b) Immunoblots of surface and total 
NMDA receptor protein. Treatment with patient IgG (isolated from serum) reduces 
surface as well as total NMDA receptor protein. GABAAα1 or actin are loading controls 
for the surface and total protein, respectively. Control NR1 levels have been overexposed 
in this image to visualize patient treated NR1 bands. (c) Quantification of surface (left) 
and total (right) NMDA receptor clusters after treatment with CSF from several patients 
with different antibody titers.  CSF from patients with higher titer decrease surface and 
total NMDA receptor clusters to a greater extent.  (d) Quantification of surface (left) and 
total (right) NMDA receptor protein after treatment with IgG from the same patient at 
two timepoints with different antibody titer.  IgG isolated from patients with a higher 
antibody titer decreased surface and total NMDAR protein to a greater extent than IgG 
isolated from the same patient when a lower antibody titer was present.  
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Figure 4.2  Patient antibodies reversibly reduce synaptic NMDA receptor clusters 
without affecting the number of synapses. 
 (a) Hippocampal neurons immunostained for total NMDA receptor clusters, a 
presynaptic glutamatergic terminal protein, VGlut, and a postsynaptic protein localized to 
glutamatergic synaspes, PSD-95.  Treatment with patient CSF for 1 day reduces the 
density of synaptic NMDA receptor clusters without affecting the number of excitatory 
synapses. After removal of patient CSF, the proportion of NMDA receptor clusters 
localized to synapses returns to baseline. Scale bar = 10 μm. (b) Quantification of the 
colocalization of pre- and postsynaptic proteins at excitatory synapses. (c) Quantification 
of the density of NMDA receptor clusters at excitatory synapses (synaptic NR1).  
Asterisk indicates significant difference (Student’s t test, p < 0.001).   
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Figure 4.3  Patient antibodies selectively decrease synaptic NMDA currents. 
 (a) mEPSCs recorded in physiological saline with TTX, bicuculline, and 0 Mg2+ 
to isolate synaptic NMDA receptor mediated currents (left upper trace). APV, an NMDA 
receptor antagonist, blocks the slow decay of mEPSCs leaving only AMPA receptor 
mediated currents which account for the fast rise of mEPSCs (left upper middle trace). 
CNQX, an AMPA receptor antagonist, blocks the fast rise of mEPSCs, allowing NMDA 
receptor mediated currents to be isolated, as indicated by asterisks (left lower middle 
trace). Both AMPA and NMDA receptor mediated synaptic currents are blocked by 
CNQX plus APV (left bottom trace). Treatment of hippocampal neurons with patient 
CSF for 1 day dramatically reduces synaptic NMDA receptor mediated currents (right).  
(b) Representative average mEPSCs from neurons treated for 1 day with control CSF 
(left) or patient CSF (right).  APV does not affect the slow decay of mEPSCs in neurons 
treated for 1 day with patient CSF, indicating that patient antibodies decrease NMDA 
receptor mediated synaptic currents. (c) Quantification of the effect of patient antibodies 
on NMDA (left) and AMPA (right) receptor mediated synaptic currents (right).  Asterisk 
indicates significant difference (Student’s t test, p < 0.001).   
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Figure 4.4 Patient antibodies bind, crosslink and internalize NMDA receptors. 
 (a) Hippocampal neurons immunostained for surface and total NMDA receptor 
clusters. Treatment with patient IgG decreases and total NMDA receptor cluster density 
(middle left).  Treatment with patient Fab fragments does not affect surface or total 
NMDA receptor cluster density (middle right), while treatment with reclustered patient 
Fab fragments decreases surface and total NMDA receptor cluster density (right).  Scale 
bar = 10 μm. (b)  Quantification of the effects of patient IgG, Fab fragments, and 
reclustered Fab fragments on surface and total NMDA receptor cluster density.  Asterisk 
indicates significant difference (Student’s t test, p < 0.001).  (c)  Schematic which 
outlines the effect of each treatment on surface receptor clusters. 
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Figure 4.5 Patients’ antibodies decrease NMDA receptor cluster density and protein 
in rodent and human hippocampus in vivo.  
  (a) After implanting a cannula into the CA1 region of  hippocampus and infusing 
control or NMDA patient CSF at a rate of ~0.5 µl/hour for 8 days, rats were euthanized, 
frozen hippocampal sections prepared and immunostained with synaptic antibodies. Brain 
sections from rats infused with control CSF (top left) contain bright and clustered NMDA 
receptor staining in CA1, while brain sections from rats infused with patient CSF (top 
right) contain significantly reduced NMDA receptor staining.  Staining for synapsin, a 
presynaptic terminal protein, is similar between control CSF and patient CSF injected rats 
(bottom left, right).  Scale bar = 2 µm. (b) Quantification of the effect of infusion of 
patient CSF with varying antibody titer on NMDA receptor cluster density in CA1. 
Patient CSF with higher antibody titers reduce NMDA receptor cluster density to a 
greater extent than low titer samples. (c)  Western blot analyses of NR1 protein in control 
and patient CSF infused rat hippocampus, ipsilateral (I) and contralateral (C) to infusion.  
NR1 protein is reduced in ipsilateral patient CSF infused hippocampus.  (d) 
Quantification of the density of synapsin labeled clusters (Student’s t test, p > 0.5). (e) 
Quantification of the density of excitatory synapses (colocalization between presynaptic 
synapsin and postsynaptic AMPA receptor clusters (Student’s t test, p > 0.5). (f) 
Hippocampal tissue section from a control patient (left) and from patient with anti-
NMDA receptor encephalitis (right) immunostained with a commercial anti-NR1 
antibody.  The intensity of NR1-immunoreactivity is dramatically reduced in the 
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hippocampi of anti-NMDA receptor encephalitis patients (N = 2) compared to 
hippocampi of control patients (N = 3).  (g) Boxed areas in f shown at higher 
magnification. Scale bars = 1 mm (top); 25 μm (bottom).  (h)  Quantification of the 
intensity of NR1 immunostaining (Student’s t test, p < 0.001).  
 
 
  
135 
  
136 
Supplemental Figure 4.1  Patient IgG treatment decreases surface and protein of 
NMDA receptor NR2A/B subunits in a titer dependent fashion. 
 (a) Immunoblots of surface and total NMDA receptor NR2A and NR2B protein.  
Treatment with patient IgG reduced surface as well as total NMDA receptor NR2A 
protein. GABAAα1 and actin are loading controls for surface and total protein, 
respectively.  (b) Quantification of surface (left) and total (right) NMDA receptor NR2A 
protein after treatment with IgG from several patients with different antibody titer.  IgG 
from patients with higher titer resulted in a greater decrease in surface and total NMDA 
receptor NR2A and NR2B protein than patients with a lower titer.  (c) Quantification of 
surface (left) and total (right) NMDA receptor NR2B protein after treatment with IgG 
from several patients with different antibody titer.  IgG from patients with higher titer 
resulted in a greater decrease in surface and total NMDA receptor NR2B protein than 
patients with a lower titer. 
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Supplemental Figure 4.2  Patient CSF treatment does not affect other synaptic 
components. 
 (a) Hippocampal neurons immunostained for an excitatory postsynaptic protein, 
PSD-95, excitatory presynaptic protein, VGlut, and surface clusters of AMPA receptor 
subunits GluR1 or GluR2. Scale bar = 10 μm. (b) Quantification of excitatory synaptic 
protein density.  Treatment with patient CSF did not affect the density of these excitatory 
synaptic proteins.  (c) Immunoblots of excitatory postsynaptic proteins, AMPA receptor 
subunits GluR2/3, excitatory postsynaptic protein PSD-95 and GABAA receptors. 
Treatment with patient IgG did not affect surface or total neurotransmitter receptor or 
excitatory synapse protein levels.  
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Supplemental Figure 4.3  Patient CSF treatment does not affect dendritic spines or 
branching. 
 (a) Hippocampal neurons transfected with the fluorescent protein, Tomato-td, 
imaged before and after one day of treatment with control or patient CSF, and traced with 
NeuronJ. Control (top) or patient (bottom) CSF treatment did not affect dendritic 
branching or complexity. Scale bar = 100 μm. (b) Quantification of primary dendrite 
number. (c) Quantification of primary dendrite length (Student’s t test, p > 0.05). (d) 
Sholl analysis of dendrite complexity before (white) and after (black) one day of control 
(left) or patient CSF (middle) treatment. Comparison of the difference before and after 
control and patient CSF treatment (right).  (e) Hippocampal neurons transfected with 
Tomato-td and treated for one day with control or patient CSF.  Control (top) or patient 
(bottom) CSF treatment did not affect dendritic protrusion density. Scale bar = 5 μm. (f) 
Quantification of the density of dendritic protrusions (Student’s t test, p > 0.05). 
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Supplemental Figure 4.4  Patient CSF treatment does not affect mEPSC frequency 
or amplitude. 
 (a) Quantification of mEPSC amplitude in neurons treated with and without 
control, patient CSF, and APV.  The total mEPSC amplitude (which represents the 
amount of functional postsynaptic AMPA receptors) is not significantly different among 
control, patient CSF or APV conditions (Kruskal-Wallis nonparametric ANOVA test 
followed by Dunn’s pairwise multiple comparison test). (b) Quantification of mEPSC 
frequency in neurons treated with and without control, patient CSF, and APV. The 
frequency of mEPSCs (which represents the number of excitatory synapses) is not 
significantly different between control, patient CSF or APV conditions (Kruskal-Wallis 
nonparametric ANOVA test followed by Dunn’s pairwise multiple comparison test). 
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Supplemental Figure 4.5  Patient antibody Fab fragments colocalize with NMDA 
receptor clusters. 
 (a) Hippocampal neurons immunostained for NMDA receptor clusters in neurons 
treated for 1 day with control IgG (top row), patient IgG (middle top), patient IgG 
clustered with anti-Fab secondary antibodies (middle), patient Fab fragments (middle 
bottom), patient Fab fragments reclustered with anti-Fab secondary antibodies (bottom). 
Color overlays of NR1 (red) and human IgG (green) are shown at right.  While patient 
IgG and patient IgG + anti-Fab stain neurons more intensely, patient Fab fragments and 
patient Fab fragments + anti-Fab colocalize with NMDARs to a similar extent. Scale bar 
= 10 μm. 
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Supplemental Figure 4.6  Patient IgG and CSF treatment have similar effects and 
these effects are not mediated via the complement pathway. 
 (a) Quantification of hippocampal neurons immunostained for surface NMDA 
receptor clusters treated with Control IgG, CSF, patient IgG, CSF, and heat inactivated 
patient CSF. Treatment with patient IgG and CSF for one day decrease surface NMDARs 
to a similar extent. Heat inactivated patient CSF also decrease surface NMDARs to a 
similar extent as patient IgG and CSF, suggesting that these effects are not mediated by 
complement-mediated pathways. (b) Quantification of dissociated hippocampal neurons 
immunostained for total NMDARs treated with Control IgG, CSF, patient IgG, CSF, and 
heat inactivated patient CSF (Kruskal-Wallis nonparametric ANOVA test followed by 
Dunn’s pairwise multiple comparison test) 
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Supplemental Figure 4.7  Patient CSF recognizes NMDA receptor clusters in vivo. 
 (a) Rat brain sections immunostained with patient CSF (top left), NMDA 
receptors (top middle), and a postsynaptic protein, PSD-95 (top right).  Patient CSF 
clusters are highly colocalized with NMDARs (yellow puncta, bottom left).  Patient CSF 
clusters colocalize with PSD-95 to a similar extent as NMDARs (compare bottom middle 
to bottom right). 
 
  
149 
  
150 
Supplemental Figure 4.8  Infusion of patient CSF results in the deposition of human 
IgG in the hippocampus without increasing cell death. 
 (a) Brain sections from rats infused with control (left) or patient CSF (right) into 
one hippocampus, and immunostained with human IgG, NR1, and TO-PRO to label 
nuclei. The deposition of human IgG was seen in the hippocampus of rats infused with 
patient CSF but not control CSF.  Below, higher magnification views of the CA1 region 
of the hippocampus show that areas with human IgG deposits have reduced NMDA 
receptor clusters (see Fig. 5) and decreased overall staining intensity. (b) Brain sections 
from rats infused with control or patient CSF and immunostained with NR1 to label 
NMDA receptors, TO-PRO to label nuclei, and TUNEL to label apoptotic cells. Infusion 
with control (left) or patient CSF (middle) did not cause significant cell death. While 
several apoptotic cells were found along the cannula tract (right), the total number and 
distribution did not differ between rats infused with control or patient CSF.  (b) 
Quantification of the density of dissociated hippocampal cells in vitro between control or 
patient CSF treatment (left) and of the percent of TUNEL positive neurons in vitro 
(apoptotic cells).  These measures were not significantly different between control or 
patient CSF treatment (Student’s t test). 
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Conclusions 
 
 The work described in the previous chapters extends our understanding of how 
neuron-glia signaling modulates GABAergic synapse formation in the developing CNS 
and how autoantibodies in patients with anti-NMDAR encephalitis disrupt synapse 
maintenance in the diseased nervous system. In particular, I have demonstrated that 
proteins secreted from astrocytes specifically increase GABAergic axon length, branch, 
and synaptogenesis and identified the astrocyte soluble proteins in size fractions that 
promote these effects. I have also shown that antibodies from anti-NMDAR encephalitis 
patients reversibly alter the number and distribution of glutamate receptors in neurons, 
resulting in a decrease in excitatory synapse function which most likely underlies the 
cognitive dysfunctions that characterize this immune-mediated encephalitis. Thus, these 
findings extend our understanding of how neuron-glial communication modulates the 
formation of synapses and how the disruption of synapse maintenance may underlie 
cognitive deficits in the diseased nervous system. 
 This work raises important questions for future research into the formation of 
GABAergic synapses. First, the differential regulation of glutamatergic and GABAergic 
synaptogenesis by astrocytes (Chapter 2) highlights the need for more in depth research 
into the mechanisms underlying synapse formation of different cell types. Recent work 
identifying transcription factors and secreted and cell adhesion molecules that specifically 
regulate GABAergic synapse development (Paradis et al., 2007; Ango et al., 2008; Lin et 
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al., 2008) has set the stage for understanding how astrocytes differentially modulate 
glutamatergic and GABAergic synaptogenesis. Second, the generation of a transgenic 
mouse model with astrocytes in which exocytosis is deficient (Pascual et al., 2005) 
provides a new tool to begin to examine the mechanisms governing the release of 
proteins from astrocytes that affect GABAergic neurons and synapses. Since astrocyte 
calcium elevations have been implicated in mediating the release of transmitters from 
astrocytes that affect neurons (Scemes and Giaume, 2006)); but also see ((Fiacco et al., 
2007), it will also be important to investigate how astrocyte activity may play a role in 
the release of proteins that increase GABAergic synaptogenesis.  Third, studies have 
shown that astrocytes from different regions differ in their ability to modulate neurite 
outgrowth (Qian et al., 1992), therefore it will be important to examine whether local 
astrocytes support synaptogenesis in a manner distinct from target-derived or other cues. 
In addition, it will be important to evaluate the ability of both immature and mature 
astrocytes to affect GABAergic neurons. Recent work has shown that only immature 
astrocytes express thrombospondins, which have been shown to increase excitatory 
synaptogenesis (Christopherson et al., 2005). This future work will be critical to 
understanding how astrocytes modulate synaptic connections in the developing and 
mature brain and will ultimately contribute to neurodevelopmental disorders such as 
epilepsy, autism and mental retardation, in which synapse formation, function, 
maintenance are aberrant or reduced.  
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 The identification of proteins contained within gel filtration fractions that increase 
GABAergic axon length, branching, and synaptogenesis (Chapter 3) lays the foundation 
for several future experiments, with the ultimate goal of evaluating the effects of 
astrocytes on the development of GABAergic synapses in vivo.  The 34 candidates 
identified in the bioactive fractions of astrocyte conditioned media can be individually 
tested by treating neuron only cultures with three different concentrations of the 
recombinant protein for three days. These cultures will be immunostained for GAD and 
VGAT to identify GABAergic neuron neurite morphology and presynaptic terminal 
density. In this manner, these candidates can be evaluated in a relatively short period of 
time.  Once a candidate is confirmed in these in vitro assays, the role of that candidate in 
mediating the effects of astrocytes in vivo can be examined using transgenic and knock-
out mouse models. Recently, several groups have used different approaches to identified 
single candidates or families of proteins from large groups of potential candidates 
(Kurusu et al., 2008; Linhoff et al., 2009). These approaches and others will be necessary 
as proteomic and genomic techniques provide increasingly detailed information about the 
processes that underlie synapse formation and development. 
 The identification of cellular mechanisms underlying anti-NMDAR encephalitis 
(Chapter 4) raises many important questions for future research into this and another 
diseases that cause synapse dysfunction. The most important future goal is to confirm the 
repertoire of pathogenic affects of autoantibodies in in vivo models of anti-NMDAR 
encephalitis. The generation of an animal model with similar features of the human 
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disease, including production of autoantibodies and disruption of blood-brain barrier 
integrity to allow antibodies access to the CNS, will allow further examination of the key 
mechanisms of this disorder.  One issue of interest is to determine what effect anti-
NMDAR autoantibodies have on hippocampal circuit plasticity, in particular LTP and 
LTD, and to attempt to directly relate this to behavior in in vivo models.  It will also be 
essential to investigate the immunological mechanisms of disease onset, in particular to 
understand the parameters that affect continued intrathecal production of antibodies 
observed in patients with this and related disorders.  Research into new treatments that 
may interfere with the pathogenic properties or actions of autoantibodies against the 
NMDA receptors will help provide better outcomes to patients. Ultimately, understanding 
the cellular, synaptic and circuit mechanisms and consequences of anti-NMDAR 
encephalitis will provide important information that can be leveraged to make progress in 
other psychiatric disorders involving glutamate receptor dysfunction, such as 
schizophrenia. 
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